CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2022 GI Fellow Board of Advisors
Embassy of Education  
Slide Library Publications Webcasts Abstract Library Committee Members
 
NASH | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care
 

J Multidiscip Healthc. 2022 Jul 19;15:1533-1545. doi: 10.2147/JMDH.S367607. eCollection 2022.

Michael K Porayko 1, Amy Articolo 2, Wendy Cerenzia 3, Brandon Coleman 3, Daxa Patel 2, Sylvie Stacy 3
 
2.Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis
 

J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1057-1068. doi: 10.1016/j.jceh.2022.01.011.Epub 2022 Feb 1.

Alexander J Kovalic 1 2
 
3.Combination Therapies for Nonalcoholic Fatty Liver Disease
 

J Pers Med. 2022 Jul 18;12(7):1166. doi: 10.3390/jpm12071166.

Evangelia S Makri 1, Eleftheria Makri 1, Stergios A Polyzos 1
 
4.Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
 

Nat Rev Endocrinol. 2022 Jul 15. doi: 10.1038/s41574-022-00711-5.Online ahead of print.

Amedeo Lonardo 1, Alessandro Mantovani 2, Salvatore Petta 3, Amedeo Carraro 4, Christopher D Byrne 5 6, Giovanni Targher 7
 
5.Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives
 

Aliment Pharmacol Ther. 2022 Aug;56(4):570-579. doi: 10.1111/apt.17121.Epub 2022 Jul 6.

Cheng Han Ng 1, Wen Hui Lim 1, Yip Han Chin 1, Jie Ning Yong 1, Rebecca Wenling Zeng 1, Kai En Chan 1, Darren Jun Hao Tan 1, Clarissa Elysia Fu 1, Ansel Shao Pin Tang 1, Lay Hoon Goh 2, Kamala Devi 3, Nicholas W S Chew 1 4, Lung-Yi Loey Mak 5, Nobuharu Tamaki 6 7, Daniel Q Huang 1 8 9, Mazen Noureddin 10, Mohammad Shadab Siddiqui 11, Rohit Loomba 6, Arun J Sanyal 11, Mark Muthiah 1 8 9
 
6.The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis
 

Clin Nutr. 2022 Jul 2;41(9):1913-1931. doi: 10.1016/j.clnu.2022.06.037. Online ahead of print.

Laura Haigh 1, Colette Kirk 2, Khalil El Gendy 3, Jennifer Gallacher 4, Linda Errington 5, John C Mathers 3, Quentin M Anstee 4
 
7.Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis
 

EClinicalMedicine. 2022 Jul 1;50:101534. doi: 10.1016/j.eclinm.2022.101534.eCollection 2022 Aug.

Adam Minich 1, Fakhar Ali Qazi Arisar 2 3 4, Noor-Ul Saba Shaikh 2, Leanne Herman 1, Amirhossein Azhie 2, Ani Orchanian-Cheff 5, Keyur Patel 3 6, Sareh Keshavarzi 7 8, Mamatha Bhat 2 3
 
8.Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
 

Nat Med. 2022 Jul;28(7):1432-1438. doi: 10.1038/s41591-022-01861-9.Epub 2022 Jun 20

Stephen A Harrison 1, Federico Perez Manghi 2, William B Smith 3, Diana Alpenidze 4, Diego Aizenberg 5, Naomi Klarenbeek 6, Chi-Yi Chen 7, Eli Zuckerman 8, Eric Ravussin 9, Phunchai Charatcharoenwitthaya 10, Pin-Nan Cheng 11, Helena Katchman 12, Samuel Klein 13, Ziv Ben-Ari 14, Anisha E Mendonza 15, Yiming Zhang 16, Miljen Martic 17, Shenglin Ma 15, Sheena Kao 18, Sandra Tanner 17, Alok Pachori 15, Michael K Badman 15, YanLing He 15, Chinweike Ukomadu 15, Eric Sicard 19
 
9.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
 

Lancet Gastroenterol Hepatol. 2022 Jul 4;S2468-1253(22)00165-0.doi: 10.1016/S2468-1253(22)00165-0. Online ahead of print.

Kiarash Riazi 1, Hassan Azhari 2, Jacob H Charette 2, Fox E Underwood 3, James A King 3, Elnaz Ehteshami Afshar 1, Mark G Swain 2, Stephen E Congly 4, Gilaad G Kaplan 3, Abdel-Aziz Shaheen 5
 
10.Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study
 

Eur J Epidemiol. 2022 Jul;37(7):723-733. doi: 10.1007/s10654-022-00868-3.Epub 2022 Apr 30.

Shuai Yuan 1, Jie Chen 2 3, Xue Li 4 5, Rongrong Fan 6, Benoit Arsenault 7 8, Dipender Gill 9 10 11 12, Edward L Giovannucci 13 14, Ju-Sheng Zheng # 15, Susanna C Larsson # 16 17
 
11.Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials
 

Nutrients. 2022 Jul 12;14(14):2846. doi: 10.3390/nu14142846.

Danielle Lee 1 2, Laura Chiavaroli 1 2, Sabrina Ayoub-Charette 1 2, Tauseef A Khan 1 2, Andreea Zurbau 1 2 3, Fei Au-Yeung 1 2 3, Annette Cheung 1 2, Qi Liu 1 2, Xinye Qi 1 2, Amna Ahmed 1 2, Vivian L Choo 1 2 4, Sonia Blanco Mejia 1 2, Vasanti S Malik 1 5, Ahmed El-Sohemy 1, Russell J de Souza 1 2 6 7, Thomas M S Wolever 1 3 8, Lawrence A Leiter 1 2 8 9 10, Cyril W C Kendall 1 2 11, David J A Jenkins 1 2 8 9 10, John L Sievenpiper 1 2 8 9 10
 
12.The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis
 

Kans J Med. 2022 Jul 21;15:241-246. doi: 10.17161/kjm.vol15.16522. eCollection 2022.

Umar Hayat 1, Muhammad Zubair Ashfaq 2, Luke Johnson 1, Ryan Ford 1, Chelsea Wuthnow 1, Kevin Kadado 1, Katia El Jurdi 1, Hayrettin Okut 3, William Ransom Kilgore 1 4, Maha Assi 1 5, Ali A Siddiqui 6
 
13.Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals
 

Endocr Pract. 2022 Jul;28(7):667-672. doi: 10.1016/j.eprac.2022.03.016.Epub 2022 Mar 29.

Jingxuan Quek 1, Cheng Han Ng 2, Ansel Shao Pin Tang 1, Nicholas Chew 3, Mark Chan 3, Chin Meng Khoo 4, Chen Poh Wei 1, Yip Han Chin 1, Phoebe Tay 1, Grace Lim 5, Darren Jun Hao Tan 1, Wen Hui Lim 1, Kai En Chan 1, Margaret Teng 6, Eunice Tan 7, Nobuharu Tamaki 8, Daniel Q Huang 7, Mohammad Shadab Siddiqui 9, Dan Yock Young 6, Mazen Noureddin 10, Mark D Muthiah 11
 
14.Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment
 

Liver Int. 2022 Aug;42(8):1772-1782. doi: 10.1111/liv.15324. Epub 2022 Jun 9.

Patrice Lazure 1, Jeremy W Tomlinson 2, Kris V Kowdley 3, Paolo Magni 4 5 6, Raul D Santos 6 7 8, Ginny Jacobs 9, Suzanne Murray 1
 
15.The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review
 

Pharmacoeconomics. 2022 Aug;40(8):751-776. doi: 10.1007/s40273-022-01140-y.Epub 2022 Jul 5.

Michal Witkowski 1, Søren Ilsøe Moreno 2, João Fernandes 2, Pierre Johansen 3, Margarida Augusto 4, Sunita Nair 5
 
16.Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
 

BMC Gastroenterol. 2022 Jun 30;22(1):323. doi: 10.1186/s12876-022-02401-y.

Kushala W M Abeysekera 1 2, James G Orr 3, Fiona H Gordon 3, Laura D Howe 4 5, Julian Hamilton-Shield 6, Jon Heron 4, Matthew Hickman 4 5
 
17.The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis
 

Inflamm Bowel Dis. 2022 Jun 3;28(6):878-887. doi: 10.1093/ibd/izab199.

Shaya Noorian 1 2, Yejoo Jeon 1 2, Minh T Nguyen 2, Jenny Sauk 1 2, Berkeley N Limketkai 1 2
 
18.A minority of somatically mutated genes in pre-existing fatty liver disease have prognostic importance in the development of NAFLD
 

Liver Int. 2022 Aug;42(8):1823-1835. doi: 10.1111/liv.15283. Epub 2022 May 11.

Jake P Mann 1 2, Matthew Hoare 2 3
 
19.A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma
 

FASEB J. 2022 Jul;36(7):e22372. doi: 10.1096/fj.202200346R.

Christopher D Green 1, Cynthia Weigel 1, Ryan D R Brown 1, Pierre Bedossa 2 3, Mikhail Dozmorov 4, Arun J Sanyal 2, Sarah Spiegel 1
 
20.Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis
 

Obes Surg. 2022 Aug;32(8):2495-2503. doi: 10.1007/s11695-022-06150-5. Epub 2022 Jun 17.

Thomas Karlas # 1, David Petroff # 2 3, Jürgen Feisthammel 4, Sebastian Beer 4, Matthias Blüher 3 5, Tatjana Schütz 3, Ralf Lichtinghagen 6, Albrecht Hoffmeister 4, Johannes Wiegand 7
 
21.American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)
 

Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

Kenneth Cusi 1, Scott Isaacs 2, Diana Barb 3, Rita Basu 4, Sonia Caprio 5, W Timothy Garvey 6, Sangeeta Kashyap 7, Jeffrey I Mechanick 8, Marialena Mouzaki 9, Karl Nadolsky 10, Mary E Rinella 11, Miriam B Vos 12, Zobair Younossi 13
 
22.Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
 

Int J Mol Sci. 2022 Jun 23;23(13):6996. doi: 10.3390/ijms23136996.

Pallavi Subramanian 1, Jochen Hampe 2, Frank Tacke 3, Triantafyllos Chavakis 1 4 5
 
23.Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease
 

Ann Gastroenterol. 2022 May-Jun;35(3):234-242. doi: 10.20524/aog.2022.0705.Epub 2022 Mar 25.

Nikolaos D Karakousis 1 2, Lampros Chrysavgis 2, Antonios Chatzigeorgiou 2 3, George Papatheodoridis 1, Evangelos Cholongitas 4
 
24.Mediterranean Diet: The Beneficial Effects of Lycopene in Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2022 Jun 16;11(12):3477. doi: 10.3390/jcm11123477.

Ludovico Abenavoli 1, Anna Caterina Procopio 1, Maria Rosaria Paravati 1, Giosuè Costa 1 2 3, Nataša Milic 4, Stefano Alcaro 1 2 3, Francesco Luzza 1
 
25.Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
 

Curr Atheroscler Rep. 2022 Jul;24(7):515-532. doi: 10.1007/s11883-022-01027-5.Epub 2022 May 4.

Nicholas W S Chew 1, Cheng Han Ng 2, Mark Dhinesh Muthiah 3, Arun J Sanyal 4
 
26.Understanding the cellular interactome of non-alcoholic fatty liver disease
 

JHEP Rep. 2022 Jun 15;4(8):100524. doi: 10.1016/j.jhepr.2022.100524.eCollection 2022 Aug.

Sebastian J Wallace 1, Frank Tacke 2, Robert F Schwabe 2 3 4 5, Neil C Henderson 1 6
 
27.Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques
 

Obes Rev. 2022 Jun 12. doi: 10.1111/obr.13481. Online ahead of print.

Willy Theel 1 2, Bianca M Boxma-de Klerk 3, Femme Dirksmeier-Harinck 4, Elisabeth F C van Rossum 2 5, Danny A Kanhai 6, Jan Apers 7, Bas M van Dalen 8, Robert J de Knegt 9, Anthony G Holleboom 10, Maarten E Tushuizen 11, Diederick E Grobbee 12 13, Janneke Wiebolt 1 2, Manuel Castro Cabezas 1 5 13
 
28.The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review
 

Life (Basel). 2022 Jun 5;12(6):839. doi: 10.3390/life12060839.

Thomas Pixner 1 2, Nathalie Stummer 2 3, Anna Maria Schneider 2 3, Andreas Lukas 1 2, Karin Gramlinger 1, Valérie Julian 4, David Thivel 5, Katharina Mörwald 2 3, Katharina Maruszczak 2 3, Harald Mangge 6, Julian Gomahr 2 3, Daniel Weghuber 2 3, Dieter Furthner 1 2
 
29.The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications
 

J Clin Med. 2022 Jun 24;11(13):3649. doi: 10.3390/jcm11133649.

Rossella Palma 1, Annamaria Pronio 1, Mario Romeo 2, Flavia Scognamiglio 2, Lorenzo Ventriglia 2, Vittorio Maria Ormando 3, Antonietta Lamazza 4, Stefano Pontone 5, Alessandro Federico 2, Marcello Dallio 2
 
30.One size does not fit all; practical, personal tailoring of the diet to NAFLD patients
 

Liver Int. 2022 Jun 8. doi: 10.1111/liv.15335. Online ahead of print.

Shira Zelber-Sagi 1 2, Laura Sol Grinshpan 1 2, Dana Ivancovsky-Wajcman 1 2, Ariela Goldenshluger 3, Yftach Gepner 3
 
31.Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
 

Cureus. 2022 May 30;14(5):e25495. doi: 10.7759/cureus.25495.eCollection 2022 May.

Gashaw Hassen 1 2 3 4, Abhishek Singh 5, Gizeshwork Belete 6, Nidhi Jain 7 8 9, Ivonne De la Hoz 10, Genesis P Camacho-Leon 11 12, Nitsuh K Dargie 13, Keila G Carrera 14, Tadesse Alemu 15, Sharan Jhaveri 16, Nebiyou Solomon 15
 
32.Growth hormone deficiency and NAFLD: An overlooked and underrecognized link
 

Hepatol Commun. 2022 Jun 28. doi: 10.1002/hep4.1953. Online ahead of print.

Iliana Doycheva 1, Dana Erickson 2, Kymberly D Watt 3
 
33.Bariatric surgery and non-alcoholic fatty liver disease
 

Med Clin (Barc). 2022 Jun 10;158(11):550-555. doi: 10.1016/j.medcli.2021.12.003.Epub 2022 Feb 2.

Helena Julià 1, David Benaiges 2, Juan Pedro-Botet 3
 
34.NAFLD: Mechanisms, Treatments, and Biomarkers
 

Biomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.

Fatiha Nassir 1
 
35.COVID-19 and liver diseases, what we know so far
 

World J Clin Cases. 2022 May 6;10(13):3969-3980.doi: 10.12998/wjcc.v10.i13.3969.

Mohamed Elnaggar 1, Ahmed Abomhya 2, Ismail Elkhattib 3, Nabila Dawoud 4, Rajkumar Doshi 5
 
36.When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
 

J Clin Med. 2022 Jun 8;11(12):3286. doi: 10.3390/jcm11123286.

Alba Rojano-Toimil 1 2, Jesús Rivera-Esteban 2 3 4, Ramiro Manzano-Nuñez 2 4, Juan Bañares 2 4, David Martinez Selva 2 5, Pablo Gabriel-Medina 6 7, Roser Ferrer 6, Juan M Pericàs 2 4 8, Andreea Ciudin 1 2 3 5
 
37.Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants
 

Gastroenterology. 2022 Jul 1;S0016-5085(22)00735-1. doi: 10.1053/j.gastro.2022.06.073.Online ahead of print.

Veeral Ajmera 1, Beom Kyung Kim 2, Kun Yang 3, Abdul M Majzoub 4, Tarek Nayfeh 5, Nobuharu Tamaki 6, Namiki Izumi 7, Atsushi Nakajima 8, Ramazan Idilman 9, Mesut Gumussoy 9, Digdem Kuru Oz 10, Ayse Erden 10, Natalie E Quach 3, Xin Tu 3, Xinlian Zhang 3, Mazen Noureddin 11, Alina M Allen 12, Rohit Loomba 13
 
38.Effect of Dietary and Lifestyle Interventions on the Amelioration of NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study
 

Nutrients. 2022 May 26;14(11):2223. doi: 10.3390/nu14112223.

Sofía Montemayor 1 2, Cristina Bouzas 1 2 3, Catalina M Mascaró 1 2, Miguel Casares 4, Isabel Llompart 1 2 5, Itziar Abete 3 6, Escarlata Angullo-Martinez 1 2 7, María Ángeles Zulet 3 6, J Alfredo Martínez 6 8, Josep A Tur 1 2 3
 
39.Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine
 

Biomedicines. 2022 May 20;10(5):1184. doi: 10.3390/biomedicines10051184.

Livianna Carrieri 1, Alberto Ruben Osella 2, Fausto Ciccacci 3, Gianluigi Giannelli 4, Maria Principia Scavo 1
 
40.Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis
 

World J Hepatol. 2022 May 27;14(5):1025-1037. doi: 10.4254/wjh.v14.i5.1025.

Nicole Cianci 1, Mohsan Subhani 2, Trevor Hill 2, Amardeep Khanna 2, Dong Zheng 3, Abhishek Sheth 2, Colin Crooks 2, Guruprasad P Aithal 2
 
41.Risk stratification of adolescents for the screening of non-alcoholic fatty liver disease
 

Pediatr Obes. 2022 May 2;e12924. doi: 10.1111/ijpo.12924. Online ahead of print.

Gary A Abrams 1, Deanna Ware 2 3, Margaret M Byrne 4, Eric M Hecht 3 5 6
 
42.Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial
 

Nutrients. 2022 May 23;14(10):2178. doi: 10.3390/nu14102178.

Giuseppina Costabile 1 2, Giuseppe Della Pepa 1, Dominic Salamone 1, Delia Luongo 3, Daniele Naviglio 4, Valentina Brancato 5, Carlo Cavaliere 5, Marco Salvatore 5, Paola Cipriano 1, Marilena Vitale 1, Alessandra Corrado 1, Angela Albarosa Rivellese 1 2, Giovanni Annuzzi 1 2, Lutgarda Bozzetto 1 2
 
43.Lipid balance must be just right to prevent development of severe liver damage
 

J Clin Invest. 2022 Jun 1;132(11):e160326. doi: 10.1172/JCI160326.

Timothy F Osborne 1, Peter J Espenshade 2
 
44.Alcohol Consumption: Medical Implications, the Liver and Beyond
 

Alcohol Alcohol. 2022 May 10;57(3):283-291. doi: 10.1093/alcalc/agac013.

Víctor Meza 1, Jorge Arnold 2, Luis Antonio Díaz 2, María Ayala Valverde 3, Francisco Idalsoaga 2, Gustavo Ayares 2, Deepika Devuni 4, Juan Pablo Arab 2
 
45.Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease
 

Am J Gastroenterol. 2022 Jun 1;117(6):927-930. doi: 10.14309/ajg.0000000000001726.Epub 2022 Mar 14.

Eleonora Scorletti 1 2, Kate Townsend Creasy 1, Marijana Vujkovic 1, Mara Vell 2 3, Inuk Zandvakili 1 4, Daniel J Rader 1 4, Kai Markus Schneider 3 5, Carolin V Schneider 1 4
 
46.Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
 

JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.

Aidan J McGlinchey 1, Olivier Govaere 2, Dawei Geng 3, Vlad Ratziu 4, Michael Allison 5, Jerome Bousier 6, Salvatore Petta 7, Claudia de Oliviera 8, Elisabetta Bugianesi 9, Jörn M Schattenberg 10, Ann K Daly 2, Tuulia Hyötyläinen 3, Quentin M Anstee 2 11, Matej Orešic 1 12
 
47.Endothelial Dysfunction in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
 

Life (Basel). 2022 May 11;12(5):718. doi: 10.3390/life12050718.

Panagiotis Theofilis 1, Aikaterini Vordoni 1, Nikolaos Nakas 2, Rigas G Kalaitzidis 1
 
48.Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
 

Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185.doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14.

P Barton Duell, Francine K Welty, Michael Miller, Alan Chait, Gmerice Hammond, Zahid Ahmad, David E Cohen, Jay D Horton, Gregg S Pressman, Peter P Toth, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease
 
49.Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography
 

Clin Gastroenterol Hepatol. 2022 May;20(5):e1149-e1156. doi: 10.1016/j.cgh.2021.08.038.Epub 2021 Aug 28.

Zobair M Younossi 1, Sean Felix 2, Thomas Jeffers 2, Elena Younossi 2, Brian Lam 2, Fatema Nader 3, Henry A Tran 4, Ingrid Schneider 5, Maria Stepanova 3
 
50.Breakthroughs in therapies for NASH and remaining challenges
 

J Hepatol. 2022 Jun;76(6):1263-1278. doi: 10.1016/j.jhep.2022.04.002.

Vlad Ratziu 1, Sven Francque 2, Arun Sanyal 3
 
51.Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis
 

J Clin Gastroenterol. 2022 Jun 1. doi: 10.1097/MCG.0000000000001727. Online ahead of print.

Hirsh D Trivedi 1, Emily W Lopes 2 3, Jeremy Glissen Brown 1, Shaan Dudani 4, Michelle Lai 1, Joseph D Feuerstein 1, Theodore T Pierce 5
 
52.Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease
 

Metabolism. 2022 May;130:155179. doi: 10.1016/j.metabol.2022.155179.Epub 2022 Mar 10.

Theodor Baars 1, Robert K Gieseler 2, Polykarpos C Patsalis 3, Ali Canbay 4
 
53.Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
 

N World J Clin Pediatr. 2022 Mar 23;11(3):221-238. doi: 10.5409/wjcp.v11.i3.221.eCollection 2022 May 9.

Simona Riccio 1, Rosa Melone 1, Caterina Vitulano 1, Pierfrancesco Guida 1, Ivan Maddaluno 1, Stefano Guarino 1, Pierluigi Marzuillo 1, Emanuele Miraglia Del Giudice 1, Anna Di Sessa 2
 
54.Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
 

Ann Gastroenterol. May-Jun 2022;35(3):213-225. doi: 10.20524/aog.2022.0704.Epub 2022 Apr 7.

Emmanouil Sinakos 1, Christina Liava 1, Rohit Loomba 2
 
55.Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
 

Lancet Gastroenterol Hepatol. 2022 Apr 28;S2468-1253(22)00061-9.doi: 10.1016/S2468-1253(22)00061-9. Online ahead of print.

Stuart McPherson 1, Matthew J Armstrong 2, Jeremy F Cobbold 3, Lynsey Corless 4, Quentin M Anstee 5, Richard J Aspinall 6, Stephen T Barclay 7, Paul N Brennan 8, Tessa M Cacciottolo 9, Robert D Goldin 10, Kate Hallsworth 5, Vanessa Hebditch 11, Kathryn Jack 12, Helen Jarvis 13, Jill Johnson 14, Wenhao Li 15, Dina Mansour 16, Mary McCallum 17, Ashis Mukhopadhya 17, Richard Parker 18, Valerie Ross 15, Ian A Rowe 19, Ankur Srivastava 20, Prarthana Thiagarajan 12, Alexandra I Thompson 21, Jeremy Tomlinson 22, Emmanuel A Tsochatzis 23, Andrew Yeoman 24, William Alazawi 15
 
56.Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
 

J Hepatol. 2022 Feb;76(2):458-463. doi: 10.1016/j.jhep.2021.09.029.Epub 2021 Oct 2.

Gyorgy Baffy 1, Jaume Bosch 2
 
57.Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD
 

J Clin Exp Hepatol. Jan-Feb 2022;12(1):174-179. doi: 10.1016/j.jceh.2021.08.002.Epub 2021 Aug 8.

Yamini Natarajan 1 2, Rohit Loomba 3
 
58.Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science
 

J Clin Transl Hepatol. 2022 Apr 28;10(2):374-382. doi: 10.14218/JCTH.2021.00408.Epub 2021 Oct 22.

Yasser Fouad 1, Melissa Palmer 2 3, Minjun Chen 4, Arie Regev 5, Rajarshi Banerjee 6, Rob Myers 7, Robert Riccio 8, Richard Torstenson 9, Ramy Younes 10, Puneet S Arora 11, Henrik Landgren 12, Morten A Karsdal 13, Martin Blake 14, David A Shapiro 15, Hans-Juergen Gruss 8, Muhammad Y Sheikh 16, Dina Attia 17, Steven Bollipo 18 19, Alastair D Smith 8, Bradley Freilich 20, Robert G Gish 21, Detlef Schuppan 22 23
 
59.A Low Glycemic Index Mediterranean Diet Combined with Aerobic Physical Activity Rearranges the Gut Microbiota Signature in NAFLD Patients
 

Nutrients. 2022 Apr 23;14(9):1773. doi: 10.3390/nu14091773.

Francesco Maria Calabrese 1, Vittoria Disciglio 2, Isabella Franco 2, Paolo Sorino 2, Caterina Bonfiglio 2, Antonella Bianco 2, Angelo Campanella 2, Tamara Lippolis 2, Pasqua Letizia Pesole 2, Maurizio Polignano 2, Mirco Vacca 1, Giusy Rita Caponio 2, Gianluigi Giannelli 2, Maria De Angelis 1, Alberto Ruben Osella 2
 
60.Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
 

Hepatology. 2022 Jan;75(1):219-228. doi: 10.1002/hep.32163. Epub 2021 Dec 10.

Pere Ginès 1 2 3 4, Laurent Castera 5 6 7, Frank Lammert 8 9 10, Isabel Graupera 1 2 3 4, Miquel Serra-Burriel 11, Alina M Allen 12, Vincent Wai-Sun Wong 13, Phillipp Hartmann 14, Maja Thiele 15, Llorenç Caballeria 16, Robert J de Knegt 17, Ivica Grgurevic 18, Salvador Augustin 3 19 20, Emmanuel A Tsochatzis 21, Jörn M Schattenberg 22, Indra Neil Guha 23, Andrea Martini 24, Rosa M Morillas 3 20 25, Montserrat Garcia-Retortillo 26, Harry J de Koning 27, Núria Fabrellas 2 28, Judit Pich 29, Ann T Ma 1 2 4, M Alba Diaz 30, Dominique Roulot 31, Philip N Newsome 32 33, Michael Manns 8, Patrick S Kamath 12, Aleksander Krag 15, LiverScreen Consortium Investigators
 
61.Novel therapeutic targets for cholestatic and fatty liver disease
 

Gut. 2022 Jan;71(1):194-209. doi: 10.1136/gutjnl-2021-324305. Epub 2021 Oct 6.

Michael Trauner 1, Claudia Daniela Fuchs 2
 
62.Inflammation in obesity, diabetes, and related disorders
 

Immunity. 2022 Jan 11;55(1):31-55. doi: 10.1016/j.immuni.2021.12.013.

Theresa V Rohm 1, Daniel T Meier 2, Jerrold M Olefsky 1, Marc Y Donath 3
 
63.Non-alcoholic Fatty Liver Disease: Also a Disease of the Brain? A Systematic Review of the Preclinical Evidence
 

Neurochem Res. 2022 Mar 1. doi: 10.1007/s11064-022-03551-x. Online ahead of print.

Anne Catrine Daugaard Mikkelsen 1, Kristoffer Kjærgaard 2, Rajeshwar Prosad Mookerjee 2 3, Hendrik Vilstrup 2, Gregers Wegener 4, Cecilie Bay-Richter 4, Karen Louise Thomsen 2 3
 
64.Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
 

Eur J Prev Cardiol. 2022 May 6;29(6):938-946.doi: 10.1093/eurjpc/zwab212.

Livnat Alon 1, Bernadette Corica 1, Valeria Raparelli 2 3, Roberto Cangemi 1, Stefania Basili 1, Marco Proietti 4 5 6, Giulio Francesco Romiti 1
 
65.Advancing the global public health agenda for NAFLD: a consensus statement
 

Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78.doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27.

Jeffrey V Lazarus 1 2, Henry E Mark 3, Quentin M Anstee 4 5, Juan Pablo Arab 6, Rachel L Batterham 7, Laurent Castera 8, Helena Cortez-Pinto 9, Javier Crespo 10, Kenneth Cusi 11, M Ashworth Dirac 12, Sven Francque 13 14, Jacob George 15, Hannes Hagström 16, Terry T-K Huang 17, Mona H Ismail 18, Achim Kautz 19, Shiv Kumar Sarin 20, Rohit Loomba 21 22, Veronica Miller 23, Philip N Newsome 24, Michael Ninburg 25, Ponsiano Ocama 26, Vlad Ratziu 27, Mary Rinella 28, Diana Romero 29, Manuel Romero-Gómez 30, Jörn M Schattenberg 31, Emmanuel A Tsochatzis 32 33, Luca Valenti 34 35, Vincent Wai-Sun Wong 36, Yusuf Yilmaz 37 38, Zobair M Younossi 39, Shira Zelber-Sagi 40 41, NAFLD Consensus Consortium

Collaborators, Affiliations collapse

  • NAFLD Consensus Consortium: 

Fredrik Åberg, Leon Adams, Maryam Salem Al Khatry, Khalid Al Naamani, Omar Alfaro Murillo, Alina M Allen, Faisal Alnaser, Saleh A Alqahtani, Khalid Alswat, Domenico Alvaro, Raúl J Andrade, Marco Arrese, Yaw Asante Awuku, Motala Ayesha, Oidov Baatarkhuu, Shokhista Bakieva, Rita Basu, Ramon Bataller, Shahinaz Bedri, Emanuele Bosi, Marc Bourliere, Radan Bruha, Elisabetta Bugianesi, Patrizia Burra, Maria Buti, Christopher D Byrne, Jose Luis Calleja, Patrizia Carrieri, Flloyd Carter, Marlen Ivon Castellanos Fernandez, Gabriela Castillo-Lopez, Graciela E Castro-Narro, Henry Lik Yuen Chan, Wah-Kheong Chan, Yoosoo Chang, Massimo Colombo, Kirsten J Coppell, Kathleen Corey, Antonio Craxi, Donna Cryer, Anuradha Dassanayake, Antonieta de Ascenção Soares Martins, Victor de Ledinghen, Stefano DelPrato, Alessandro Demaio, Hailemichael Desalegn, John Dillon, Ajay Duseja, Prabhakaran Dorairaj, Mattias Ekstedt, Mohamed El Kassas, Osama M Elsanousi, Gamal Esmat, Jian-Gao Fan, Nathalie Farpour-Lambert, Robert Flisiak, Yasser Fouad, Michael Fuchs, Rino A Gani, Lynn Gerber, Hasmik Ghazinyan, Liana Gheorghe, George Boon-Bee Goh, Henning Grønbæk, Aghayeva Gulnara, Saeed Hamid, Vanessa Hebditch, Ingrid J Hickman, Samantha L Hocking, Bela Hunyady, Ramazan Idilman, Vasily A Isakov, Mohammad H Jamal, Peter Jepsen, Natacha Jreige Iskandar, Myeong Jun Song, K C Sudhamshu, Satoru Kakizaki, George Kalamitsis, Fasiha Kanwal, Jia-Horng Kao, Lee Kaplan, Takumi Kawaguchi, Yousef Khader, Seung Up Kim, Nicolas Kodjoh, Ger Koek, Kazuhiko Koike, Narcisse Patrice Komas, Marko Korenjak, Marcelo Kugelmas, Asma Labidi, Naomi F Lange, Joel E Lavine, Mariana Lazo, Nancy Lee, Cosmas Rinaldi A Lesmana, Chun-Jen Liu, Michelle T Long, Patricio Lopez-Jaramillo, Reza Malekzadeh, Mamun Al Mahtab, Giulio Marchesini, Rui Marinho, Sophia E Martínez Vázquez, Lyudmila Mateva, Charles Mbendi Nlombi, Pascal Melin, Ivana Mikolasevic, Tamara Milovanovic, Carla Musso, Atsushi Nakajima, Edna Nava, Alexander V Nersesov, Dafina Nikolova, Suzanne Norris, Katja Novak, Jude Oben, Janus P Ong, Charles Onyekwere, George Papatheodoridis, Imran Paruk, Keyur Patel, M Paula Macedo, Carlos Penha-Gonçalves, Marlene Pérez Figueroa, Wolf Peter Hofmann, Salvatore Petta, Claudia Pinto Marques Souza de Oliveira, Puneet Puri, Calvin Q Pan, Marek Rac, Johanna Ralston, Alnoor Ramji, Homie Razavi, Mario Reis Alvares-da-Silva, Stuart Roberts, Michael Roden, Tamsin Rose, Samir Rouabhia, Patrizia Rovere-Querini, Ian A Rowe, Shakhlo Sadirova, Riina Salupere, Tobokalova Saparbu, Raymond Sayegh, Giada Sebastiani, Yosuke Seki, Josefina Selmo, 
 
66.Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
 

Clin Gastroenterol Hepatol. 2022 Mar;20(3):511-524.e1.doi: 10.1016/j.cgh.2021.03.017. Epub 2021 Mar 13.

Pichamol Jirapinyo 1, Thomas R McCarty 1, Russell D Dolan 1, Raj Shah 2, Christopher C Thompson 3
 
67.Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease
 

Aliment Pharmacol Ther. 2022 Apr;55(8):894-907. doi: 10.1111/apt.16879.Epub 2022 Mar 11.

Mohammad Zamani 1 2, Shaghayegh Alizadeh-Tabari 2, Siddharth Singh 3, Rohit Loomba 4
 
68.Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes
 

Clin Mol Hepatol. 2022 Jan;28(1):52-66. doi: 10.3350/cmh.2021.0205.Epub 2021 Sep 17.

Hydar El Jamaly 1 2, Guy D Eslick 3, Martin Weltman 1 2
 
69.PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
 

Int J Mol Sci. 2022 Feb 28;23(5):2707. doi: 10.3390/ijms23052707.

Rosa Lombardi 1 2, Roberto Piciotti 1 2, Paola Dongiovanni 1, Marica Meroni 1, Silvia Fargion 1 2, Anna Ludovica Fracanzani 1 2
 
70.Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations
 

Drug Metab Dispos. 2022 Apr;50(4):492-499. doi: 10.1124/dmd.121.000413.Epub 2021 Sep 16.

Solène Marie 1, David K K Tripp 1, Nathan J Cherrington 2
 
71.Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
 

Endocrinol Diabetes Metab. 2022 May;5(3):e00335. doi: 10.1002/edm2.335.Epub 2022 Apr 6.

Adrian Vilalta 1, Julio A Gutiérrez 1 2, SuZanne Chaves 1, Moisés Hernández 1, Silvia Urbina 1, Marcus Hompesch 1
 
72.Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
 

Clin Pharmacol Ther. 2022 Apr 16. doi: 10.1002/cpt.2614. Online ahead of print.

William A Murphy 1, Jeffry Adiwidjaja 1 2, Noora Sjöstedt 3, Kyunghee Yang 4, James J Beaudoin 4, Jessica Spires 2, Scott Q Siler 4, Sibylle Neuhoff 5, Kim L R Brouwer 1
 
73.Inhibition of 11ß-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study
 

Diabetes Obes Metab. 2022 May;24(5):881-890.doi: 10.1111/dom.14646.Epub 2022 Jan 25.

Yogesh Yadav 1, Kelly Dunagan 2, Rachita Khot 3, Sudhakar K Venkatesh 2, John Port 2, Alfonso Galderisi 4, Claudio Cobelli 4, Craig Wegner 5, Ananda Basu 1, Rickey Carter 6, Rita Basu 1
 
74.Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies
 

J Intern Med. 2022 Jan;291(1):11-31. doi: 10.1111/joim.13380. Epub 2021 Sep 26.

Youngmin A Lee 1, Scott L Friedman 2
 
75.Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis
 

Biomolecules. 2022 Jan 8;12(1):105. doi: 10.3390/biom12010105.

Stefano Ciardullo 1 2, Cinzia Ballabeni 3, Roberto Trevisan 2 4, Gianluca Perseghin 1 2
 
76.Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
 

Gut. 2022 May;71(5):1006-1019. doi: 10.1136/gutjnl-2021-324243.Epub 2021 May 17.

Ferenc Emil Mózes 1, Jenny A Lee 2, Emmanuel Anandraj Selvaraj 1 3 4, Arjun Narayan Ajmer Jayaswal 1, Michael Trauner 5, Jerome Boursier 6 7, Céline Fournier 8, Katharina Staufer 5 9 10, Rudolf E Stauber 11, Elisabetta Bugianesi 12, Ramy Younes 13, Silvia Gaia 12, Monica Lup?or-Platon 14, Salvatore Petta 15, Toshihide Shima 16, Takeshi Okanoue 16, Sanjiv Mahadeva 17, Wah-Kheong Chan 17, Peter J Eddowes 18 19, Gideon M Hirschfield 20, Philip Noel Newsome 18 21 22, Vincent Wai-Sun Wong 23, Victor de Ledinghen 24 25, Jiangao Fan 26, Feng Shen 26, Jeremy F Cobbold 3 4, Yoshio Sumida 27, Akira Okajima 28, Jörn M Schattenberg 29, Christian Labenz 29, Won Kim 30, Myoung Seok Lee 31, Johannes Wiegand 32, Thomas Karlas 32, Yusuf Yilmaz 33 34, Guruprasad Padur Aithal 19 35, Naaventhan Palaniyappan 19 35, Christophe Cassinotto 36, Sandeep Aggarwal 37, Harshit Garg 37, Geraldine J Ooi 38, Atsushi Nakajima 39, Masato Yoneda 39, Marianne Ziol 40, Nathalie Barget 41, Andreas Geier 42, Theresa Tuthill 43, M Julia Brosnan 43, Quentin Mark Anstee 44, Stefan Neubauer 1, Stephen A Harrison 1, Patrick M Bossuyt 2, Michael Pavlides 45 3 4, LITMUS Investigators
 
77.Effect of a Six-Month Lifestyle Intervention on the Physical Activity and Fitness Status of Adults with NAFLD and Metabolic Syndrome
 

Nutrients. 2022 Apr 26;14(9):1813. doi: 10.3390/nu14091813.

Catalina M Mascaró 1 2, Cristina Bouzas 1 2 3, Sofia Montemayor 1 2, Miguel Casares 4, Isabel Llompart 1 2 5, Lucía Ugarriza 1 2 6, Pere-Antoni Borràs 7, J Alfredo Martínez 8 9, Josep A Tur 1 2 3
 
78.Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool
 

Sci Rep. 2022 Apr 20;12(1):6485.doi: 10.1038/s41598-022-10481-9.

Ambrin Farizah Babu # 1 2, Susanne Csader # 1, Ville Männistö 3, Milla-Maria Tauriainen 1 3, Heikki Pentikäinen 4, Kai Savonen 4 5, Anton Klåvus 2, Ville Koistinen 1 2 6, Kati Hanhineva 1 2 6, Ursula Schwab 7 8
 
79.Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies
 

Gut. 2022 Apr;71(4):778-788. doi: 10.1136/gutjnl-2021-324191.Epub 2021 Mar 8.

Alessandro Mantovani 1, Graziana Petracca 1, Giorgia Beatrice 1, Alessandro Csermely 1, Herbert Tilg 2, Christopher D Byrne 3, Giovanni Targher 4
 
80.Treatment Candidacy for Pharmacologic Therapies for NASH
 

Clin Gastroenterol Hepatol. 2022 Jun;20(6):1209-1217.doi: 10.1016/j.cgh.2021.03.005. Epub 2021 Mar 10.

Ian A Rowe 1, Vincent Wai-Sun Wong 2, Rohit Loomba 3
 
81.NAFLD in normal weight individuals
 

Diabetol Metab Syndr. 2022 Mar 24;14(1):45. doi: 10.1186/s13098-022-00814-z.

Johanna K DiStefano 1, Glenn S Gerhard 2
 
82.A new perspective on NAFLD: Focusing on lipid droplets
 

J Hepatol. 2022 Apr;76(4):934-945. doi: 10.1016/j.jhep.2021.11.009.Epub 2021 Nov 15.

Eleonora Scorletti 1, Rotonya M Carr 2
 
83.Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
 

Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0.Epub 2021 Nov 23.

Nobuharu Tamaki 1 2, Veeral Ajmera 1, Rohit Loomba 3 4
 
84.Fatty Liver Disease: Diagnosis and Stratification
 

Annu Rev Med. 2022 Jan 27;73:529-544.doi: 10.1146/annurev-med-042220-020407. Epub 2021 Nov 22.

Yedidya Saiman 1, Andres Duarte-Rojo 2, Mary E Rinella 3
 
85.Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
 

Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244. Online ahead of print.

Jennifer R Kramer 1 2, Yamini Natarajan 1 3, Jianliang Dai 4, Xian Yu 1, Liang Li 4, Hashem B El-Serag 3, Fasiha Kanwal 1 3
 
86.Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
 

Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049.Epub 2021 Sep 20.

Fasiha Kanwal 1, Jay H Shubrook 2, Leon A Adams 3, Kim Pfotenhauer 4, Vincent Wai-Sun Wong 5, Eugene Wright 6, Manal F Abdelmalek 6, Stephen A Harrison 7, Rohit Loomba 8, Christos S Mantzoros 9, Elisabetta Bugianesi 10, Robert H Eckel 11, Lee M Kaplan 12, Hashem B El-Serag 1, Kenneth Cusi 13
 
87.A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery
 

J Nutr. 2022 Feb 8;152(2):408-418. doi: 10.1093/jn/nxab392.

Silke Crommen 1, Karl Peter Rheinwalt 2, Andreas Plamper 2, Marie-Christine Simon 3, Daniela Rösler 4, Rolf Fimmers 5, Sarah Egert 1 6, Christine Metzner 4 7
 
88.Obesity and Nonalcoholic Fatty Liver Disease
 

Nurs Clin North Am. 2021 Dec;56(4):543-552. doi: 10.1016/j.cnur.2021.07.009.

Amanda Chaney 1
 
89.What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
 

Hepatol Commun. 2021 Nov;5(11):1810-1823. doi: 10.1002/hep4.1814.Epub 2021 Sep 9.

Naim Alkhouri # 1, Monica Tincopa # 2, Rohit Loomba # 3, Stephen A Harrison # 4 5
 
90.Role of Cholesterol-Associated Steatohepatitis in the Development of NASH
 

Hepatol Commun. 2022 Jan;6(1):12-35. doi: 10.1002/hep4.1801. Epub 2021 Aug 24.

Christian L Horn 1, Amilcar L Morales 1, Christopher Savard 2 3 4, Geoffrey C Farrell 5, George N Ioannou 2 3 4
 
91.Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
 

PLoS One. 2022 Apr 15;17(4):e0266859.doi: 10.1371/journal.pone.0266859. eCollection 2022.

Tinsay A Woreta 1, Mark L Van Natta 2, Mariana Lazo 3, Arunkumar Krishnan 1, Brent A Neuschwander-Tetri 4, Rohit Loomba 5, Anna Mae Diehl 6, Manal F Abdelmalek 6, Naga Chalasani 7, Samer Gawrieh 7, Srinivasan Dasarathy 8, Raj Vuppalanchi 7, Mohammad S Siddiqui 9, Kris V Kowdley 10, Arthur McCullough 8, Norah A Terrault 11, Cynthia Behling 5, David E Kleiner 12, Mark Fishbein 13, Paula Hertel 14, Laura A Wilson 2, Emily P Mitchell 2, Laura A Miriel 2, Jeanne M Clark 1, James Tonascia 2, Arun J Sanyal 9, NASH Clinical Research Network
 
92.Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis
 

Clin J Gastroenterol. 2021 Dec;14(6):1579-1586. doi: 10.1007/s12328-021-01491-7.Epub 2021 Aug 9.

Adnan Malik 1, Mahum Nadeem 2, Muhammad Imran Malik 3
 
93.Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
 

Gastroenterol. 2022 May;57(5):357-371.doi: 10.1007/s00535-022-01860-0. Epub 2022 Mar 24.

Javier Ampuero # 1 2 3, Rocío Gallego-Durán # 4 5, Douglas Maya-Miles 4 5, Rocío Montero 4 5, Sheila Gato 4 5, Ángela Rojas 4 5, Antonio Gil 4 5, Rocío Muñoz 4 5, Manuel Romero-Gómez 6 4 5
 
94.Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review
 

Semin Liver Dis. 2021 Nov;41(4):435-447. doi: 10.1055/s-0041-1731704.Epub 2021 Jul 9.

Anas Hashem 1, Amani Khalouf 1, Andres Acosta 1
 
95.The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis
 

J Clin Endocrinol Metab. 2022 Feb 17;107(3):862-881.doi: 10.1210/clinem/dgab795.

Angelo Sabag 1 2, Loren Barr 2, Mike Armour 1 3, Alex Armstrong 4, Callum J Baker 5, Stephen M Twigg 5 6, Dennis Chang 1, Daniel A Hackett 4, Shelley E Keating 7, Jacob George 8, Nathan A Johnson 4 9
 
96.Genome-Wide Association Study of NAFLD Using Electronic Health Records
 

Hepatol Commun. 2022 Feb;6(2):297-308. doi: 10.1002/hep4.1805.Epub 2021 Sep 17.

Cameron J Fairfield 1, Thomas M Drake 1, Riinu Pius 1, Andrew D Bretherick 2, Archie Campbell 1 3 4, David W Clark 5, Jonathan A Fallowfield 6, Caroline Hayward 2, Neil C Henderson 6, Peter K Joshi 5, Nicholas L Mills 7, David J Porteous 3, Prakash Ramachandran 6, Robert K Semple 7, Catherine A Shaw 1, Cathie L M Sudlow 1, Paul R H J Timmers 2 5, James F Wilson 2 5, Stephen J Wigmore 8, Ewen M Harrison # 1 8, Athina Spiliopoulou # 5
 
97.Is there an 'ideal' diet for patients with NAFLD?
 

Eur J Clin Invest. 2022 Mar;52(3):e13659. doi: 10.1111/eci.13659. Epub 2021 Aug 2

Nicola Pugliese 1 2, Maria Corina Plaz Torres 2 3, Salvatore Petta 4, Luca Valenti 5 6, Edoardo G Giannini 3, Alessio Aghemo 1 2
 
98.Nonalcoholic Fatty Liver Disease in Children
 

Gastroenterol Hepatol (N Y). 2021 Dec;17(12):579-587.

Katherine F Sweeny 1, Christine K Lee 1 2
 
99.A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
 

Aliment Pharmacol Ther. 2022 Jan;55(2):234-243. doi: 10.1111/apt.16720. Epub 2021 Dec 5.

Jeffrey V Lazarus 1 2, Henry E Mark 2, Massimo Colombo 2 3, Sandro Demaio 4, John F Dillon 5, Jacob George 6, Hannes Hagström 7, Samantha Hocking 6, Nancy Lee 8, Mark J Nieuwenhuijsen 1, Mary E Rinella 9, Manuel Romero-Gomez 10, Joan B Soriano 11, Jörn M Schattenberg 12, Frank Tacke 13, Emmanuel A Tsochatzis 14, Luca Valenti 3, Shira Zelber-Sagi 15 16, M Ashworth Dirac 17, Terry T-K Huang 18
 
100.Liver Disease: Nonalcoholic Fatty Liver Disease
 

FP Essent. 2021 Dec;511:29-35.

Julia Cooper 1, Katrina Baumgartner 2, Andrew Smith 2, Joshua St Louis 2
 
101.Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease
 

Children (Basel). 2022 Mar 8;9(3):374. doi: 10.3390/children9030374.

Eduardo Castillo-Leon 1 2, Heather L Morris 3, Cheryl Schoen 3, Jacob Bilhartz 4, Patrick McKiernan 5, Tamir Miloh 6, Sirish Palle 7, Mohammad Nasser Kabbany 8, Breda Munoz 3, Andrea R Mospan 3, Bryan Rudolph 9, Stavra A Xanthakos 10, Miriam B Vos 11, Target-Nash Investigators
 
102.Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis
 

Aliment Pharmacol Ther. 2021 Dec;54(11-12):1405-1415. doi: 10.1111/apt.16664.Epub 2021 Oct 20.

Rifaat Safadi 1, Marius Braun 2, Adi Francis 3, Yael Milgrom 1, Muhammad Massarwa 1, David Hakimian 1, Wadi Hazou 1, Assaf Issachar 2, Zivit Harpaz 4, Motti Farbstein 4, Inbal Itzhak 4, Naama Lev-Cohain 5, Avital Bareket-Samish 6, Michael H Silverman 4, Pnina Fishman 4
 
103.Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
 

Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7.

Arun J Sanyal 1, Quentin M Anstee 2, Michael Trauner 3, Eric J Lawitz 4, Manal F Abdelmalek 5 6, Dora Ding 7, Ling Han 7, Catherine Jia 7, Ryan S Huss 7, Chuhan Chung 7, Vincent Wai-Sun Wong 8, Takeshi Okanoue 9, Manuel Romero-Gomez 10, Andrew J Muir 5 6, Nezam H Afdhal 11, Jaime Bosch 12 13, Zachary Goodman 14, Stephen A Harrison 15, Zobair M Younossi 14, Robert P Myers 7
 
104.Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design
 

Diabetes Metab. 2022 Mar;48(2):101281. doi: 10.1016/j.diabet.2021.101281.Epub 2021 Sep 17.

Pierpaolo Pellicori 1, Muthiah Vaduganathan 2, João Pedro Ferreira 3, Faiez Zannad 4, Arun J Sanyal 5
 
105.Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
 

Am J Gastroenterol. 2021 Dec 1;116(12):2399-2409.doi: 10.14309/ajg.0000000000001375.

Stephen A Harrison 1, Seth J Baum 2, Nadege T Gunn 3, Ziad H Younes 4, Anita Kohli 5, Rashmee Patil 6, Margaret J Koziel 7, Harinder Chera 7, Jeff Zhao 7, Manu V Chakravarthy 7
 
106.Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin
 

J Pediatr. 2021 Dec;239:161-167.e5.doi: 10.1016/j.jpeds.2021.08.012. Epub 2021 Aug 13.

Samer Gawrieh 1, Kathryn E Harlow 2, Francis Pike 3, Katherine P Yates 4, Laura A Wilson 4, Oscar W Cummings 5, William M Rosenberg 6, Naga Chalasani 7, Jean P Molleston 2
 
107.JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk
 

J Clin Lipidol. Mar-Apr 2022;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007.

Kathleen L Wyne 1, Sheldon E Litwin 2, Kenneth Cusi 3, John R Guyton 4
 
108.Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):458-460.e4. doi: 10.1016/j.cgh.2021.03.031.Epub 2021 Mar 26.

Mary J Thomson 1, Marina Serper 2, Vandana Khungar 2, L Michael Weiss 3, Huy Trinh 4, Roberto Firpi-Morell 5, Michael Roden 6, Rohit Loomba 7, A Sidney Barritt 4th 8, Derek Gazis 9, Andrea R Mospan 9, Michael W Fried 9, K Rajender Reddy 2, Anna S Lok 10
 
109.The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
 

J Hepatol. 2022 Apr;76(4):771-780. doi: 10.1016/j.jhep.2021.10.025. Epub 2021 Dec 9.

Jeffrey V Lazarus 1, Henry E Mark 2, Marcela Villota-Rivas 3, Adam Palayew 4, Patrizia Carrieri 5, Massimo Colombo 6, Mattias Ekstedt 7, Gamal Esmat 8, Jacob George 9, Giulio Marchesini 10, Katja Novak 11, Ponsiano Ocama 12, Vlad Ratziu 13, Homie Razavi 14, Manuel Romero-Gómez 15, Marcelo Silva 16, C Wendy Spearman 17, Frank Tacke 18, Emmanuel A Tsochatzis 19, Yusuf Yilmaz 20, Zobair M Younossi 21, Vincent W-S Wong 22, Shira Zelber-Sagi 23,  Helena Cortez-Pinto 24, Quentin M Anstee 25, NAFLD policy review collaborators

Collaborators

  • NAFLD policy review collaborators: 

Samir Rouabhia  26 , Hasmik Ghazinyan   27,  Natacha Jreige Iskandar  28, Michael Trauner   29,  Gulnara Aghayeva  30, Flloyd Carter   31, Kannan Sridharan   32, Mamun Al Mahtab   33, Sven Francque   34, Nicolas Kodjoh   35,  Ruben Muñoz Camacho  36, Motswedi Anderson   37,  Claudia Pinto Marques Souza de Oliveira  38,  Lyudmila Mateva  39, Abdel Karim Serme   40,  Antonieta A Soares Martins  41,  Mark G Swain  42,  Narcisse Patrice Komas  43, Ming-Hua Zheng   44, Patricio Lopez Jaramillo   45, Omar Alfaro Murillo   46,  Ivana Mikolasevic  47, Emmelia Vounou   48, Radan Bruha   49, Charles Mbendi Nlombi   50, Maja Thiele   51, Marlene Perez   52, Juan José Suárez M  53,  Imam Waked  54, Riina Salupere   55, Hailemichael Desalegn   56, Hannele Yki-Järvinen 57, Tengiz Tsertsvadze 58, Lali Sharvadze 58, Maia Butsashvili 58, Yaw Asante Awuku 59, Georgios Papatheodoridis 60, Bela Hunyady 61, Einar Stefan Bjornsson 62, Ajay Duseja 63, Cosmas Rinaldi A Lesmana 64, Reza Malekzadeh 65, Suzanne Norris 66, Kazuhiko Koike 67, Alexander V Nersesov 68, Missiani Ochwoto 69, Mohammad Jamal 70, Tobokalova Saparbu 71, Ieva Tolmane 72, Raymond Sayegh 73, Dhastagir Sultan Sheriff 74, Jonas Valantinas 75, Joseph Weber 76, Isaac Thom Shawa 77, Soek-Siam Tan 78, Sophia E Martínez Vázquez 79, Oidov Baatarkhuu 80, Undram Lkhagvaa 80, Tsolmon Jadamba 80, Tahiri Mohammed 81, K C Sudhamshu 82, Kirsten Coppell 83 , Charles Onyekwere 84,&nbs
 
110.Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
 

BMJ Open. 2022 Mar 30;12(3):e056159. doi: 10.1136/bmjopen-2021-056159.

Neeta B Amin 1, Amanda Darekar 2, Quentin M Anstee 3, Vincent Wai-Sun Wong 4, Frank Tacke 5, Manoli Vourvahis 6, Douglas S Lee 7, Michael Charlton 8, Naim Alkhouri 9, Atsushi Nakajima 10, Carla Yunis 6
 
111.Perspective: Is it Time to Expand Research on 'Nuts' to Include 'Seeds'? Justifications and Key Considerations
 

Adv Nutr. 2022 Mar 25;nmac028. doi: 10.1093/advances/nmac028. Online ahead of print.

Elena S George 1, Robin M Daly 1, Siew Ling Tey 2, Rachel Brown 2, Tommy Hon Ting Wong 3, Sze-Yen Tan 1
 
112.Perspective: Is it Time to Expand Research on
 

Adv Nutr. 2022 Mar 25;nmac028. doi: 10.1093/advances/nmac028. Online ahead of print.

Elena S George 1, Robin M Daly 1, Siew Ling Tey 2, Rachel Brown 2, Tommy Hon Ting Wong 3, Sze-Yen Tan 1
 
113.Metabolic dysfunction-related liver disease as a risk factor for cancer
 

BMJ Open Gastroenterol. 2022 Mar;9(1):e000817. doi: 10.1136/bmjgast-2021-000817.

Alasdair Taylor 1, Moneeza K Siddiqui 1, Philip Ambery 2, Javier Armisen 3, Benjamin G Challis 4, Carolina Haefliger 5, Ewan R Pearson 1, Alex S F Doney 1, John F Dillon 6, Colin N A Palmer 7
 
114.Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score
 

Hepatology. 2022 Mar 25. doi: 10.1002/hep.32475. Online ahead of print.

Rish K Pai 1, Vipul Jairath 2 3 4, Malcolm Hogan 3, Guangyong Zou 3 4 5, Oyedele A Adeyi 6, Quentin M Anstee 7 8, Bashar A Aqel 9, Cynthia Behling 10 11, Elizabeth J Carey 9, Andrew D Clouston 12, Kathleen Corey 13 14, Brian G Feagan 2 3 4, David E Kleiner 15, Christopher Ma 3 16 17, Stefanie C McFarlane 3, Mazen Noureddin 18, Vlad Ratziu 19, Mark A Valasek 20, Zobair M Younossi 21 22, Stephen A Harrison 23 24, Rohit Loomba 25
 
115.Impact of a Mediterranean Diet on Hepatic and Metabolic outcomes in Non-Alcoholic Fatty Liver Disease: The MEDINA Randomised Controlled Trial
 

Liver Int. 2022 Mar 31. doi: 10.1111/liv.15264. Online ahead of print.

Elena S George 1 2, Anjana Reddy 2, Amanda J Nicoll 3, Marno Ryan 4, Catherine Itsiopoulos 2 5, Gavin Abbott 1, Nathan A Johnson 6, Siddharth Sood 7, Stuart K Roberts 8 9, Audrey C Tierney 2 10
 
116.Bariatric Surgery in NAFLD
 

Dig Dis Sci. 2022 Feb;67(2):408-422. doi: 10.1007/s10620-021-07317-3.Epub 2022 Jan 4.

Mahak Chauhan 1, Kuldeep Singh 1, Paul J Thuluvath 2 3
 
117.Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials
 

Expert Opin Investig Drugs. 2022 Feb;31(2):163-172. doi:10.1080/13543784.2022.2032640.Epub 2022 Feb 10.

Pankaj Aggarwal 1, Mazen Noureddin 2, Stephen Harrison 3, Sophie Jeannin 4, Naim Alkhouri 5
 
118.Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week
 

J Am Coll Cardiol. 2022 Jan 18;79(2):180-191. doi: 10.1016/j.jacc.2021.11.007.

Alessandro Mantovani 1, Christopher D Byrne 2, Giovanni Benfari 3, Stefano Bonapace 4, Tracey G Simon 5, Giovanni Targher 6
 
119.Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE)
 

PLoS One. 2021 Nov 30;16(11):e0260320. doi: 10.1371/journal.pone.0260320.eCollection 2021.

Wayne Eskridge 1, John M Vierling 2, Wayne Gosbee 3, Gabriella A Wan 1, May-Linh Hyunh 1, Henry E Chang 1
 
120.Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care
 

J Clin Med. 2021 Dec 9;10(24):5755. doi: 10.3390/jcm10245755.

Laurence J Dobbie 1, Mohamed Kassab 2, Andrew S Davison 3 4, Pete Grace 4, Daniel J Cuthbertson 1, Theresa J Hydes 1 2
 
121.Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease
 

Biomedicines. 2022 Jan 17;10(1):195. doi: 10.3390/biomedicines10010195.

Lauren A Newman 1, Zivile Useckaite 1, Jillian Johnson 2, Michael J Sorich 1, Ashley M Hopkins 1, Andrew Rowland 1
 
122.Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography
 

Ultraschall Med. 2022 Feb 28. doi: 10.1055/a-1724-7289. Online ahead of print.

David Jm Bauer 1 2, Vladimir Matic 3, Ruxandra Mare 4, Laura Maiocchi 5, David Chromy 1 2, Theresa Müllner-Bucsics 1 2, Mattias Mandorfer 1 2, Sandra Mustapic 3, Ioan Sporea 6, Giovanna Ferraioli 5, Ivica Grgurevic 3, Thomas Reiberger 1 2 7
 
123.Life Expectancy after Liver Transplantation for NASH
 

Prog Transplant. 2022 Mar 30;15269248221087441. doi: 10.1177/15269248221087441.Online ahead of print.

Robert M Shavelle 1, Rachel C Saur 1, Ji Hun Kwak 1, Jordan C Brooks 1, Bilal Hameed 2
 
124.Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
 

Lancet Gastroenterol Hepatol. 2022 Mar 21;S2468-1253(22)00017-6.doi: 10.1016/S2468-1253(22)00017-6. Online ahead of print.

Stephen A Harrison 1, Manal F Abdelmalek 2, Guy Neff 3, Nadege Gunn 4, Cynthia D Guy 5, Naim Alkhouri 6, Mustafa R Bashir 7, Bradley Freilich 8, Anita Kohli 9, Arun Khazanchi 10, Muhammad Y Sheikh 11, Mark Leibowitz 12, Mary E Rinella 13, Mohammad S Siddiqui 14, Mark Kipnes 15, Sam E Moussa 16, Ziad H Younes 17, Meena Bansal 18, Seth J Baum 19, Brian Borg 20, Peter J Ruane 21, Paul J Thuluvath 22, Mildred Gottwald 23, Mujib Khan 23, Charles Chen 23, Liza Melchor-Khan 23, William Chang 23, Alex M DePaoli 23, Lei Ling 24, Hsiao D Lieu 23
 
125.Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
 

Metabolites. 2022 Mar 11;12(3):238. doi: 10.3390/metabo12030238.

Ryan D Welch 1, Cyrielle Billon 2, McKenna Losby 3, Gonzalo Bedia-Diaz 2, Yuanying Fang 2, Amer Avdagic 2, Bahaa Elgendy 2 4, Thomas P Burris 5, Kristine Griffett 6
 
126.Focal fatty sparing as an indicator of higher-grade fatty liver assessed by attenuation imaging: a prospective clinical study in NAFLD population
 

Z Gastroenterol. 2021 Dec 14. doi: 10.1055/a-1695-3637. Online ahead of print.

Elisabeth Miller 1, Julian Schmidberger 1, Wolfgang Kratzer 1
 
127.Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing posttransplant metabolic complications
 

Am J Transplant. 2021 Oct;21(10):3324-3332. doi: 10.1111/ajt.16583. Epub 2021 May 3.

Suzanne R Sharpton 1, Norah A Terrault 2, Mehdi M Tavakol 3, Andrew M Posselt 3
 
128.The fecal mycobiome in non-alcoholic fatty liver disease
 

J Hepatol. 2022 Apr;76(4):788-799. doi: 10.1016/j.jhep.2021.11.029. Epub 2021 Dec 10.

Münevver Demir 1, Sonja Lang 2, Phillipp Hartmann 3, Yi Duan 4, Anna Martin 5, Yukiko Miyamoto 4, Marina Bondareva 6, Xinlian Zhang 7, Yanhan Wang 4, Philipp Kasper 5, Corinna Bang 8, Christoph Roderburg 9, Frank Tacke 1, Hans-Michael Steffen 5, Tobias Goeser 5, Andrey Kruglov 6, Lars Eckmann 4, Peter Stärkel 10, Derrick E Fouts 11, Bernd Schnabl 12
 
129.Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
 

Gut. 2022 Feb;71(2):382-390. doi: 10.1136/gutjnl-2020-322564. Epub 2021 Feb 4.

Ramy Younes 1 2 3, Olivier Govaere 1, Salvatore Petta 4, Luca Miele 5 6, Dina Tiniakos 1 7, Alastair Burt 1, Ezio David 3, Fabio Maria Vecchio 5 8, Marco Maggioni 9, Daniela Cabibi 10, Duncan McLeod 11, Maria Jesus Pareja 12, Anna Ludovica Fracanzani 13, Rocio Aller 14, Chiara Rosso 3, Javier Ampuero 15, Rocío Gallego-Durán 15, Angelo Armandi 3, Gian Paolo Caviglia 3, Marco Y W Zaki 1 16, Antonio Liguori 5, Paolo Francione 13, Grazia Pennisi 4, Antonio Grieco 5 6, Giovanni Birolo 3, Piero Fariselli 3, Mohammed Eslam 17, Luca Valenti 18, Jacob George 17, Manuel Romero-Gómez 15, Quentin Mark Anstee 19 20, Elisabetta Bugianesi 21
 
130.Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease
 

J Clin Invest. 2021 Dec 15;131(24):e150996. doi: 10.1172/JCI150996.

Catherine C Cohen 1 2, Kelvin W Li 3, Adina L Alazraki 4 5, Carine Beysen 6, Carissa A Carrier 7, Rebecca L Cleeton 1, Mohamad Dandan 3, Janet Figueroa 1, Jack Knight-Scott 5, Cynthia J Knott 8, Kimberly P Newton 7 9, Edna M Nyangau 3, Claude B Sirlin 10, Patricia A Ugalde-Nicalo 7 9, Jean A Welsh 1 11, Marc K Hellerstein 3, Jeffrey B Schwimmer 7 9, Miriam B Vos 1 11
 
131.Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control
 

Nat Commun. 2022 Mar 10;13(1):1259. doi: 10.1038/s41467-022-28889-2.

Magdalene K Montgomery 1, Jacqueline Bayliss 2, Shuai Nie 3, William De Nardo 2, Stacey N Keenan 2, Paula M Miotto 2, Hamzeh Karimkhanloo 2 4, Cheng Huang 5, Ralf B Schittenhelm 5, Anthony S Don 6, Andrew Ryan 7, Nicholas A Williamson 3, Geraldine J Ooi 8, Wendy A Brown 8, Paul R Burton 8, Benjamin L Parker 2, Matthew J Watt 9
 
132.Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?
 

World J Hepatol. 2021 Dec 27;13(12):1816-1827.

doi: 10.4254/wjh.v13.i12.1816.

Huw Purssell 1, Peter J Whorwell 2, Varinder S Athwal 1, Dipesh H Vasant 2
 
133.Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants
 

J Hepatol. 2022 Jan 24;S0168-8278(22)00023-X. doi: 10.1016/j.jhep.2022.01.010.Online ahead of print.

Fanny Petermann-Rocha 1, Stuart R Gray 2, Ewan Forrest 3, Paul Welsh 2, Naveed Sattar 2, Carlos Celis-Morales 4, Frederick K Ho 5, Jill P Pell 6
 
134.Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
 

J Hepatol. 2022 Jan 25;S0168-8278(22)00024-1. doi: 10.1016/j.jhep.2022.01.011.Online ahead of print.

Elizabeth M Brunt 1, Andrew D Clouston 2, Zachary Goodman 3, Cynthia Guy 4, David E Kleiner 5, Carolin Lackner 6, Dina G Tiniakos 7, Aileen Wee 8, Matthew Yeh 9, Wei Qiang Leow 10, Elaine Chng 11, Yayun Ren 11, George Goh Boon Bee 12, Elizabeth E Powell 13, Mary Rinella 14, Arun J Sanyal 15, Brent Neuschwander-Tetri 16, Zobair Younossi 17, Michael Charlton 18, Vlad Ratziu 19, Stephen A Harrison 20, Dean Tai 21, Quentin M Anstee 22
 
135.A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study
 

Sci Rep. 2022 Feb 4;12(1):1956. doi: 10.1038/s41598-022-05168-0.

Ann M Farrell 1 2, Dianna J Magliano 3, Jonathan E Shaw 3, Alexander J Thompson 4 5, Catherine Croagh 4 5, Marno C Ryan 4 5, Jessica Howell 4 5 6 7
 
136.Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
 

J Clin Transl Hepatol. 2021 Dec 28;9(6):931-938. doi: 10.14218/JCTH.2021.00174.Epub 2021 Aug 24.

Shivaram P Singh 1, Prajna Anirvan 1, Reshu Khandelwal 1, Sanjaya K Satapathy 2
 
137.Ethnic and gender differences in hepatic lipid content and related cardiometabolic parameters in lean individuals
 

JCI Insight. 2022 Feb 15;e157906. doi: 10.1172/jci.insight.157906. Online ahead of print.

Kitt Falk Petersen 1, Sylvie Dufour 1, Fangyong Li 2, Douglas L Rothman 3, Gerald I Shulman 1
 
138.Liver biopsy for assessment of chronic liver diseases: a synopsis
 

Clin Exp Med. 2022 Feb 22. doi: 10.1007/s10238-022-00799-z.Online ahead of print.

Aqib B Chowdhury 1, Kosha J Mehta 2
 
139.NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective
 

Gastroenterology. 2022 Mar 3;S0016-5085(22)00203-7.doi: 10.1053/j.gastro.2022.01.058. Online ahead of print.

Kylynda C Bauer 1, Paula T Littlejohn 2, Victoria Ayala 3, Anna Creus-Cuadros 4, B Brett Finlay 5
 
140.Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD
 

Hepatol Commun. 2022 Mar 15. doi: 10.1002/hep4.1932. Online ahead of print.

Theresia M Schnurr 1 2, Sophia Figueroa Katz 1 3, Johanne M Justesen 1 2, Jack W O'Sullivan 1, Peter Saliba-Gustafsson 1 4, Themistocles L Assimes 1 5, Ivan Carcamo-Orive 1 6, Aijaz Ahmed 7, Euan A Ashley 1 8 9, Torben Hansen 2, Joshua W Knowles 1 6 10
 
141.Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)
 

Aliment Pharmacol Ther. 2022 Mar 17. doi: 10.1111/apt.16874. Online ahead of print.

Danielle Brandman 1, Marie Boyle 2 3, Stuart McPherson 2 3, Mark L Van Natta 4, Arun J Sanyal 5, Kris Kowdley 6, Brent Neuschwander-Tetri 7, Naga Chalasani 8, Manal F Abdelmalek 9, Norah A Terrault 10, Art McCullough 11, Ricki Bettencourt 12, Cyrielle Caussy 12, David E Kleiner 13, Cynthia Behling 14, James Tonascia 4, Quentin M Anstee 2, Rohit Loomba 12, Members of the Nonalcoholic Steatohepatitis Clinical Research Network
 
142.Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update
 

Biomedicines. 2022 Jan 17;10(1):194. doi: 10.3390/biomedicines10010194.

Laura Giuseppina Di Pasqua 1, Marta Cagna 1, Clarissa Berardo 1, Mariapia Vairetti 1, Andrea Ferrigno 1
 
143.Analysis of Liver Responses to Non-alcoholic Steatohepatitis by mRNA-Sequencing
 

Methods Mol Biol. 2022;2455:163-179. doi: 10.1007/978-1-0716-2128-8_14.

Christopher D Green 1, Mikhail G Dozmorov 2, Sarah Spiegel 3
 
144.T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
 

Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336. Online ahead of print.

Pierluigi Ramadori 1, Shing Kam 1, Mathias Heikenwalder 1
 
145.Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
 

Hepatology. 2022 Feb;75(2):473-488. doi: 10.1002/hep.32285. Epub 2022 Jan 11.

Scott L Friedman 1, Massimo Pinzani 2
 
146.The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period
 

Cells. 2022 Feb 5;11(3):562. doi: 10.3390/cells11030562.

Francesco Valentini 1, Giulia Rocchi 2, Umberto Vespasiani-Gentilucci 3, Michele Pier Luca Guarino 4, Annamaria Altomare 4, Simone Carotti 5
 
147.The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology?
 

Yasser Fouad 1, Jean-François Dufour 2 3, Ming-Hua Zheng 4 5 6, Steven Bollipo 7, Hailemichael Desalegn 8, Henning Grønbaek 9, Robert G Gish 10
 
148.A global view of the interplay between non-alcoholic fatty liver disease and diabetes
 

Lancet Diabetes Endocrinol. 2022 Feb 17;S2213-8587(22)00003-1.doi: 10.1016/S2213-8587(22)00003-1. Online ahead of print.

Norbert Stefan 1, Kenneth Cusi 2
 
149.Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes
 

Liver Int. 2022 Feb 26.doi: 10.1111/liv.15209. Online ahead of print.

Patrizia Carrieri 1, Abbas Mourad 1, Fabienne Marcellin 1, Aldo Trylesinski 2, José Luis Calleja 3, Camelia Protopopescu 1, Jeffrey V Lazarus 4 5
 
150.Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
 

touchREV Endocrinol. 2021 Nov;17(2):112-120. doi: 10.17925/EE.2021.17.2.112.Epub 2021 Sep 14.

Sherwyn Schwartz 1, Jean Lucas 2, Mark H DeLegge 3
 
151.Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients
 

Hepatol Commun. 2022 Feb 28. doi: 10.1002/hep4.1915. Online ahead of print.

Maria Stepanova 1 2, Khaled Kabbara 1 3, Denise Mohess 4, Manisha Verma 1 4, Alva Roche-Green 4, Saleh AlQahtani 2 5, Janus Ong 2 6, Patrizia Burra 2 7, Zobair M Younossi 1 2 3 8
 
152.Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium
 

Clin Gastroenterol Hepatol. 2022 Feb 18;S1542-3565(22)00184-7.doi: 10.1016/j.cgh.2022.02.028. Online ahead of print.

Mary E Rinella, Sanjaya K Satapathy, Danielle Brandman, Coleman Smith, Sal Elwir, Jonathan Xia, Meg Gibson, Carlos Figueredo, Mounika Angirekula, Jason M Vanatta, Raiya Sarwar, Yu Jiang, Dyanna Gregory, Tandy Agostini, JimIn Ko, Pradeep Podila, Grace Gallo, Kymberly D Watt, Mohammad S Siddiqui
 
153.Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011-2018
 

Clin Gastroenterol Hepatol. 2022 Mar;20(3):e610-e613. doi: 10.1016/j.cgh.2021.01.030.Epub 2021 Jan 22.

Robert J Wong 1, Ramsey Cheung 2
 
154.Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-ß and Tau Pathology in Middle-Aged Adults: The Framingham Study
 

J Alzheimers Dis. 2022 Feb 21. doi: 10.3233/JAD-215409. Online ahead of print.

Galit Weinstein 1, Adrienne O'Donnell 2 3, Kendra Davis-Plourde 2 3, Shira Zelber-Sagi 1 4, Saptaparni Ghosh 3 5, Charles S DeCarli 6, Emma G Thibault 7, Reisa A Sperling 7 8, Keith A Johnson 7 8, Alexa S Beiser 2 3 5, Sudha Seshadri 3 5 9
 
155.Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study
 

J Pediatr Gastroenterol Nutr. 2022 Feb 21. doi: 10.1097/MPG.0000000000003418.Online ahead of print.

Jake P Mann 1, Benjamin Jenkins, Samuel Furse, Stuart G Snowden, Anna Alisi, Laura G Draijer, Kylie Karnebeek, Deirdre A Kelly, Bart G Koot, Antonella Mosca, Camilla Salvestrini, Indra van Mourik, Anita Vreugdenhil, Matthias Zilbauer, Albert Koulman, EU-PNAFLD investigators^
 
156.Clinical Intervention to Reduce Dietary Sugar does not Impact Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial
 

J Nutr. 2022 Feb 26;nxac046. doi: 10.1093/jn/nxac046. Online ahead of print.

Kelsey A Schmidt 1, Roshonda B Jones 1, Claudia Rios 1, Yesica Corona 1, Paige K Berger 1, Jasmine F Plows 1, Tanya L Alderete 2, Jennifer Fogel 1, Hailey Hampson 1 3, Jaana A Hartiala 4, Zhiheng Cai 5, Hooman Allayee 5 4, Krishna S Nayak 6 7, Frank R Sinatra 3, Gregory Harlan 3, Trevor A Pickering 4, Sarah-Jeanne Salvy 8, Wendy Mack 4, Rohit Kohli 9, Michael I Goran 1
 
157.Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study
 

Nutrients. 2022 Feb 18;14(4):854. doi: 10.3390/nu14040854.

Meagan E Gray 1, Sejong Bae 2, Rekha Ramachandran 2, Nicholas Baldwin 3, Lisa B VanWagner 4 5, David R Jacobs Jr 6, James G Terry 7, James M Shikany 2
 
158.Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery
 

Hepatology. 2022 Jan 25. doi: 10.1002/hep.32358. Online ahead of print.

Raluca Pais 1 2 3 4, Judith Aron-Wisnewsky 1 2 5, Pierre Bedossa 6, Maharajah Ponnaiah 3, Jean-Michel Oppert 1 2, Jean-Michel Siksik 1, Laurent Genser 1 2 5, Frederic Charlotte 1 2, Dominique Thabut 1 2 4, Karine Clement 1 2 5, Vlad Ratziu 1 2 3 6
 
159.NASH: regulatory considerations for clinical drug development and U.S. FDA approval
 

Acta Pharmacol Sin. 2022 Jan 21. doi: 10.1038/s41401-021-00832-z. Online ahead of print.

Brian E Harvey 1
 
160.Agreement Between the Prevalence of Nonalcoholic Fatty Liver Disease Determined by Transient Elastography and Fatty Liver Indices
 

Clin Gastroenterol Hepatol. 2022 Jan;20(1):227-229.e2. doi: 10.1016/j.cgh.2020.11.028.Epub 2020 Nov 20.

Gieira S Jones 1, Christian S Alvarez 1, Barry I Graubard 1, Katherine A McGlynn 2
 
161.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
 

Gut. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082.Epub 2020 Dec 10.

Alessandro Mantovani 1, Graziana Petracca 1, Giorgia Beatrice 1, Alessandro Csermely 1, Amedeo Lonardo 2, Jörn M Schattenberg 3, Herbert Tilg 4, Christopher D Byrne 5, Giovanni Targher 6
 
162.NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):e315-e318. doi: 10.1016/j.cgh.2021.01.022.Epub 2021 Jan 16.

Monika Sarkar 1, Maya Djerboua 2, Jennifer A Flemming 3
 
163.Sleep disruption in nonalcoholic fatty liver disease: What is the role of lifestyle and diet?
 

Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e308-e312.doi: 10.1097/MEG.0000000000002049.

Siddique T Akram 1, Matthew W Ewy 2, Adnan Said 3 4
 
164.Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):256-268.doi: 10.1016/j.cgh.2020.10.018. Epub 2020 Oct 16.

Jordan E Lake 1, Turner Overton 2, Susanna Naggie 3, Mark Sulkowski 4, Rohit Loomba 5, David E Kleiner 6, Jennifer C Price 7, Kara W Chew 8, Raymond T Chung 9, Kathleen E Corey 9
 
165.Is it time for chronopharmacology in NASH?
 

J Hepatol. 2022 Jan 20;S0168-8278(22)00010-1. doi: 10.1016/j.jhep.2021.12.039.Online ahead of print.

Thomas Marjot 1, David W Ray 2, Jeremy W Tomlinson 3
 
166.Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis
 

Endocr Pract. 2022 Feb;28(2):204-213. doi: 10.1016/j.eprac.2021.12.010.Epub 2021 Dec 22.

Zobair M Younossi 1, Linda Henry 2
 
167.Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
 

Clin Gastroenterol Hepatol. 2022 Jan 6;S1542-3565(22)00002-7. doi: 10.1016/j.cgh.2021.12.044.Online ahead of print.

Eric J Lawitz 1, Bal Raj Bhandari 2, Peter J Ruane 3, Anita Kohli 4, Eliza Harting 5, Dora Ding 5, Jen-Chieh Chuang 5, Ryan S Huss 5, Chuhan Chung 5, Robert P Myers 6, Rohit Loomba 7
 
168.Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism
 

PLoS One. 2022 Jan 6;17(1):e0261555. doi: 10.1371/journal.pone.0261555. eCollection 2022.

Daniel E Radford-Smith 1 2 3, Preya J Patel 4 5, Katharine M Irvine 6 7, Anthony Russell 8 9, Dan Siskind 10 11, Daniel C Anthony 1, Elizabeth E Powell 6 12, Fay Probert 2
 
169.Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD
 

Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324. Online ahead of print.

Mary P Moore 1 2, Rory P Cunningham 1 2, Grace M Meers 1 2, Sarah A Johnson 1 3, Andrew A Wheeler 4, Rama R Ganga 4, Nicole M Spencer 4, James B Pitt 4, Alberto Diaz-Arias 5, Ahmed I A Swi 3, Ghassan M Hammoud 3, Jamal A Ibdah 1 2 3, Elizabeth J Parks 2 3, R Scott Rector 1 2 3
 
170.Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease
 

J Med Econ. 2022 Jan 17;1-29. doi: 10.1080/13696998.2022.2026702. Online ahead of print.

Vinod K Rustgi 1 2, Steve B Duff 3, Mohamed I Elsaid 1 4
 
171.Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
 

Metabol Open. 2022 Jan 5;13:100158. doi: 10.1016/j.metop.2021.100158. eCollection 2022 Mar.

David Bernstein 1, Alexander J Kovalic 1
 
172.Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2022 Feb 8;11(3):890. doi: 10.3390/jcm11030890.

Peter Lemmer 1 2, Paul Manka 1, Jan Best 1, Alisan Kahraman 3, Julia Kälsch 3, Ramiro Vilchez-Vargas 2, Alexander Link 2, Hsin Chiang 3, Guido Gerken 3, Ali Canbay 1, Lars P Bechmann 1, Svenja Sydor 1
 
173.Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!
 

Clin Investig Arterioscler. 2022 Feb 4;S0214-9168(21)00155-8. doi: 10.1016/j.arteri.2021.10.001.Online ahead of print.

[Article in English, Spanish]

Niki Katsiki 1, Anca Pantea Stoian 2, Manfredi Rizzo 3
 
174.Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease
 

Eur J Gastroenterol Hepatol. 2022 Jan 31. doi: 10.1097/MEG.0000000000002347.Online ahead of print.

Valentin Blank 1, David Petroff, Albrecht Boehlig, Aileen Heinze, Thomas Karlas, Thomas Berg, Johannes Wiegand
 
175.The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint
 

Liver Int. 2022 Feb 7. doi: 10.1111/liv.15188. Online ahead of print.

Taghreed M Farahat 1, Mehmet Ungan 2, Josep Vilaseca 3, Jacqueline Ponzo 4, Pramendra Prasad Gupta 5, Andrew D Schreiner 6, Wadeia Al Sharief 7, Kelly Casler 8, Tafat Abdelkader 9, Ludovico Abenavoli 10, Fatima-Zohra Mchich Alami 11, Mattias Ekstedt 12, Muntadar Saad Jabir 13, Matthew J Armstrong 14, Mona Osman El Hage 15, Johannes Wiegand 16, Dina Attia 17, Veronique Verhoeven 18, Ashraf Abdul Qayoum Amir 19, Nagwa Nashat 1, Emmanuel A Tsochatzis 20, Yasser Fouad 21, Helena Cortez-Pinto 22
 
176.Exposure to maternal fuels during pregnancy and offspring hepatic fat in early childhood: The healthy start study
 

Pediatr Obes. 2022 Feb 5;e12902. doi: 10.1111/ijpo.12902. Online ahead of print.

Catherine C Cohen 1 2, Ellen C Francis 2, Wei Perng 2 3 4, Katherine A Sauder 1 2, Ann Scherzinger 5, Shikha S Sundaram 1, Kartik Shankar 1 2, Dana Dabelea 1 2 3
 
177.Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies
 

J Endocrinol Invest. 2022 Feb 11. doi: 10.1007/s40618-022-01755-0.Online ahead of print.

F Bellinato 1, P Gisondi 2, A Mantovani 3, G Girolomoni 2, G Targher 3
 
178.The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States
 

Clin Gastroenterol Hepatol. 2021 Oct 16;S1542-3565(21)01131-9. doi: 10.1016/j.cgh.2021.10.018.

Zobair M Younossi 1, Michael Harring 2, Youssef Younossi 3, Janus P Ong 4, Saleh A Alqahtani 5, Maria Stepanova 6
 
179.NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH
 

Hepatology. 2021 Dec 10. doi: 10.1002/hep.32274. Online ahead of print.

Jonathan G Stine 1 2 3 4, Ian R Schreibman 1 3, Alison J Faust 1 3, Jessica Dahmus 1, Benjamin Stern 1, Christopher Soriano 1, Gloriany Rivas 1, Breianna Hummer 1, Scot R Kimball 5, Nate R Geyer 2, Vernon M Chinchilli 2, Rohit Loomba 6 7, Kathryn Schmitz 2 4 8 9, Christopher Sciamanna 2 4 10
 
180.The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology
 

Transl Res. 2021 Jul;233:5-15. doi: 10.1016/j.trsl.2020.12.010. Epub 2021 Jan 2.

James R Burton Jr 1, Steven Helmke 2, Shannon Lauriski 3, John Kittelson 3, Gregory T Everson 2
 
181.Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
 

Patient. 2021 Sep;14(5):533-543. doi: 10.1007/s40271-020-00485-w.Epub 2020 Dec 18.

Lynda C Doward 1, Maria-Magdalena Balp 2, James Twiss 3, Christina Slota 4, Donna Cryer 5, Clifford A Brass 6, Quentin M Anstee # 7 8, Arun J Sanyal # 9
 
182.Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2606-2614.e4. doi: 10.1016/j.cgh.2020.08.054.Epub 2020 Aug 31.

Mariana Lazo 1, Usama Bilal 2, Mack C Mitchell 3, James Potter 4, Ruben Hernaez 5, Jeanne M Clark 6
 
183.Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2673-2674.e3. doi: 10.1016/j.cgh.2020.11.005.Epub 2020 Nov 3.

Nobuharu Tamaki 1, Nagambika Munaganuru 2, Jinho Jung 2, Aed Qas Yonan 2, Richele Bettencourt 2, Veeral Ajmera 2, Mark A Valasek 3, Cynthia Behling 4, Rohit Loomba 5
 
184.Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study
 

Eur J Gastroenterol Hepatol. 2021 Dec 1;33(12):1578-1581.doi: 10.1097/MEG.0000000000001902.

Mahmud Mahamid 1 2, Wiliam Nseir 3, Tawfik Khoury 4 5 6, Baker Mahamid 6, Adi Nubania 1 2, Kamal Sub-Laban 1 2, Joel Schifter 1 2, Amir Mari 5 6, Wisam Sbeit 4 5, Eran Goldin 1 2
 
185.Pediatric obesity-related non-alcoholic fatty liver disease: waist-to-height ratio best anthropometrical predictor
 

Pediatr Res. 2021 Jul;90(1):166-170. doi: 10.1038/s41390-020-01192-w. Epub 2020 Oct 10.

Giuseppina R Umano 1, Anna Grandone 2, Anna Di Sessa 2, Domenico Cozzolino 3, Marcella Pedullà 2, Pierluigi Marzuillo 2, Emanuele Miraglia Del Giudice 2
 
186.Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
 

Mol Metab. 2021 Aug;50:101115. doi: 10.1016/j.molmet.2020.101115.Epub 2020 Nov 10.

Douglas G Mashek 1
 
187.Association of a 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation
 

Transplantation. 2021 Jul 1;105(7):1576-1584. doi: 10.1097/TP.0000000000003390.

Anan Abu Rmilah 1, Robert Fencl 2, Kymberly Watt 1, Michael Krowka 1, Russell Wiesner 1, David Murray 2, Scott Nyberg 1, Michael Leise 1
 
188.Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
 

J Clin Gastroenterol. 2021 Nov-Dec 01;55(10):891-902. doi: 10.1097/MCG.0000000000001409.

Robert J Wong 1, Nandita Kachru 2, Diane J Martinez 3, Meghan Moynihan 3, A Burak Ozbay 2, Stuart C Gordon 4
 
189.Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis
 

Panminerva Med. 2021 Dec;63(4):508-518. doi: 10.23736/S0031-0808.20.04171-3.Epub 2020 Nov 9.

Abdulrahman Ismaiel 1, Daniel-Corneliu Leucuta 2, Stefan-Lucian Popa 1, Sharmila Fagoonee 3, Rinaldo Pellicano 4, Ludovico Abenavoli 5, Dan L Dumitrascu 1
 
190.A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051.Epub 2020 Nov 2.

Mohammad Shadab Siddiqui 1, Michael O Idowu 2, Deven Parmar 3, Brian B Borg 4, Douglas Denham 5, Nicole M Loo 6, Donald Lazas 7, Ziad Younes 8, Arun J Sanyal 9
 
191.A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis
 

Eur J Gastroenterol Hepatol. 2021 Nov 1;33(11):1420-1426.doi: 10.1097/MEG.0000000000001882.

Karl Björkström 1, Per Stål 1 2, Magnus Holmer 1 2, Bonnie Bengtsson 1 2, Annika Staaf 1, Johan Hoffstedt 1, Hannes Hagström 1 2 3
 
192.Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)
 

Visc Med. 2021 Aug;37(4):273-280. doi: 10.1159/000515445. Epub 2021 Apr 13.

Elke Roeb 1
 
193.Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease
 

Hepatol Commun. 2021 Sep 2. doi: 10.1002/hep4.1818. Online ahead of print.

Ashwini Arvind 1 2, Jacqueline B Henson 1 3, Stephanie A Osganian 2, Cheryl Nath 2, Lara M Steinhagen 2, Zoe N Memel 1 3, Arley Donovan 2, Oluwafemi Balogun 2, Raymond T Chung 1 2 4, Tracey G Simon 1 2 4, Kathleen E Corey 1 2 4
 
194.A Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non-Alcoholic Fatty Liver Disease in Non-Obese Population
 

Cureus. 2021 Sep 10;13(9):e17869. doi: 10.7759/cureus.17869. eCollection 2021 Sep.

Olubunmi Oladunjoye 1, Adeolu O Oladunjoye 2 3, Rashmi Dhital 1, DilliRam Poudel 4, Oreoluwa D Oladiran 5, Ibiyemi O Oke 1, Gabriel Areoye 1, Asad Jehangir 6, Oluwaseun Shogbesan 7
 
195.Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry
 

Clin Gastroenterol Hepatol. 2021 Nov 9;S1542-3565(21)01183-6.doi: 10.1016/j.cgh.2021.11.004.Online ahead of print.

Zobair M Younossi 1, Yusuf Yilmaz 2, Ming-Lung Yu 3, Vincent Wai-Sun Wong 4, Marlen Castellanos Fernandez 5, Vasily A Isakov 6, Ajay K Duseja 7, Nahum Mendez-Sanchez 8, Yuichiro Eguchi 9, Elisabetta Bugianesi 10, Patrizia Burra 11, Jacob George 12, Jian-Gao Fan 13, George V Papatheodoridis 14, Wah Kheong Chan 15, Khalid Alswat 16, Hamid S Saeed 17, Ashwani K Singal 18, Manuel Romero-Gomez 19, Stuart C Gordon 20, Stuart K Roberts 21, Mohamed El Kassas 22, Marcelo Kugelmas 23, Janus P Ong 24, Saleh Alqahtani 25, Mariam Ziayee 26, Brian Lam 27, Issah Younossi 28, Andrei Racila 27, Linda Henry 29, Maria Stepanova 29, Global NASH Council
 
196.Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects
 

J Gastrointestin Liver Dis. 2021 Sep 21;30(3):366-373. doi: 10.15403/jgld-3622.

Alexandra Feldman 1, Bernhard Wernly 2, Georg Strebinger 3, Sebastian Karl Eder 4, Stephan Zandanell 5, David Niederseer 6, Michael Strasser 7, Heike Haufe 8, Karl Sotlar 9, Bernhard Paulweber 10, Christian Datz 11, Elmar Aigner 12
 
197.Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis
 

Panminerva Med. 2021 Dec;63(4):508-518. doi: 10.23736/S0031-0808.20.04171-3.Epub 2020 Nov 9.

Abdulrahman Ismaiel 1, Daniel-Corneliu Leucuta 2, Stefan-Lucian Popa 1, Sharmila Fagoonee 3, Rinaldo Pellicano 4, Ludovico Abenavoli 5, Dan L Dumitrascu 1
 
198.A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051.Epub 2020 Nov 2.

Mohammad Shadab Siddiqui 1, Michael O Idowu 2, Deven Parmar 3, Brian B Borg 4, Douglas Denham 5, Nicole M Loo 6, Donald Lazas 7, Ziad Younes 8, Arun J Sanyal 9
 
199.Non-hepatic Cancers Independently Predict Liver Decompensation Events
 

J Gastrointest Cancer. 2021 Jun;52(2):523-528. doi: 10.1007/s12029-020-00409-9.

Yuchen Wang 1, Bashar M Attar 2, Rohit Agrawal 3, Ishaan Vohra 3, Muhammad Zain Farooq 3, Sheeba Ba Aqeel 3, Melchor Demetria 2
 
200.PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Sep;19(9):1979-1981. doi: 10.1016/j.cgh.2020.09.009.Epub 2020 Sep 6.

Grazia Pennisi 1, Rosaria Maria Pipitone 2, Calogero Cammà 2, Vito Di Marco 2, Vincenzo Di Martino 2, Federica Spatola 2, Rossella Zito 2, Antonio Craxì 2, Stefania Grimaudo 2, Salvatore Petta 2
 
201.Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease
 

J Nephrol. 2021 Jun;34(3):649-659. doi: 10.1007/s40620-020-00751-y.Epub 2020 May 21.

Mehmet Kanbay 1, Mustafa C Bulbul 2, Sidar Copur 2, Baris Afsar 3, Alan A Sag 4, Dimitrie Siriopol 5, Masanari Kuwabara 6, Silvia Badarau 5, Adrian Covic 5, Alberto Ortiz 7
 
202.Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease
 

Clin Infect Dis. 2021 Jun 15;72(12):2087-2094.doi: 10.1093/cid/ciaa382.

Lindsay T Fourman 1, Takara L Stanley 1, Isabel Zheng 1, Chelsea S Pan 1, Meghan N Feldpausch 1, Julia Purdy 2, Julia Aepfelbacher 2, Colleen Buckless 3, Andrew Tsao 3, Kathleen E Corey 4, Raymond T Chung 4, Martin Torriani 3, David E Kleiner 5, Colleen M Hadigan 2, Steven K Grinspoon 1
 
203.Dynamic Positron Emission Tomography/Computed Tomography Imaging Correlate of Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2021 Nov;19(11):2441-2443. doi: 10.1016/j.cgh.2020.10.029.Epub 2020 Oct 17.

Souvik Sarkar 1, Karen E Matsukuma 2, Benjamin Spencer 3, Shuai Chen 4, Kristin A Olson 2, Ramsey D Badawi 3, Michael T Corwin 3, Guobao Wang 5
 
204.Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease
 

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1480-1488.e14. doi: 10.1016/j.cgh.2020.07.030.Epub 2020 Jul 21.

Nandini M Meyersohn 1, Thomas Mayrhofer 2, Kathleen E Corey 3, Daniel O Bittner 4, Pedro V Staziaki 5, Balint Szilveszter 5, Travis Hallett 5, Michael T Lu 5, Stefan B Puchner 6, Tracey G Simon 3, Borek Foldyna 5, Deepak Voora 7, Geoffrey S Ginsburg 7, Pamela S Douglas 8, Udo Hoffmann 5, Maros Ferencik 9
 
205.Liver Steatosis Categorization on Contrast-Enhanced CT Using a Fully Automated Deep Learning Volumetric Segmentation Tool: Evaluation in 1204 Healthy Adults Using Unenhanced CT as a Reference Standard
 

AJR Am J Roentgenol. 2021 Aug;217(2):359-367. doi: 10.2214/AJR.20.24415. Epub 2020 Sep 16.

Perry J Pickhardt 1, Glen M Blake 2, Peter M Graffy 1, Veit Sandfort 3, Daniel C Elton 3, Alberto A Perez 1, Ronald M Summers 3
 
206.Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C
 

Dig Dis Sci. 2021 Jul;66(7):2394-2406. doi: 10.1007/s10620-020-06457-2. Epub 2020 Jul 11.

Jihane N Benhammou 1 2, Andrew M Moon 3, Joseph R Pisegna 4, Feng Su 5, Philip Vutien 5, Cynthia A Moylan 6 7, George N Ioannou 3 8 9
 
207.Genetic And Epigenetic Factors Determining NAFLD Risk
 

Mol Metab. 2021 Aug;50:101111. doi: 10.1016/j.molmet.2020.101111.Epub 2020 Nov 5.

Wenke Jonas 1, Annette Schürmann 2
 
208.Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
 

Clin Gastroenterol Hepatol. 2021 Nov;19(11):22742283.e5.doi:10.1016/j.cgh.2020.08.061. Epub 2020 Aug 31.

Jonathan G Stine 1, Nagambika Munaganuru 2, Abbey Barnard 3, Jennifer L Wang 4, Kellee Kaulback 5, Curtis K Argo 6, Siddarth Singh 3, Kathryn J Fowler 7, Claude B Sirlin 7, Rohit Loomba 8
 
209.Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1240-1247.e5. doi: 10.1016/j.cgh.2020.07.023.Epub 2020 Jul 16.

Donghee Kim 1, Soumya Murag 2, George Cholankeril 3, Amanda Cheung 3, Stephen A Harrison 4, Zobair M Younossi 5, Aijaz Ahmed 3
 
210.Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)
 

EClinicalMedicine. 2021 Sep 5;40:101116. doi: 10.1016/j.eclinm.2021.101116. eCollection 2021 Oct.

Jenny Bischoff 1, Wenyi Gu 2, Carolynne Schwarze-Zander 1 3, Christoph Boesecke 1 3, Jan-Christian Wasmuth 1 3, Kathrin van Bremen 1, Leona Dold 1 3, Jürgen K Rockstroh 1 3, Jonel Trebicka 2
 
211.Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare
 

Dig Dis Sci. 2021 Sep;66(9):3186-3191. doi: 10.1007/s10620-020-06588-6. Epub 2020 Sep 7.

Gabrielle Ritaccio # 1, Gianna Stoleru # 1, Ameer Abutaleb 2, Raymond K Cross 2, Kirti Shetty 2, Sasan Sakiani 2, Uni Wong 3
 
212.Habitual coffee intake and risk for nonalcoholic fatty liver disease: a two-sample Mendelian randomization study
 

Eur J Nutr. 2021 Jun;60(4):1761-1767. doi: 10.1007/s00394-020-02369-z.Epub 2020 Aug 27.

Yang Zhang # 1, Zhipeng Liu # 2, Tasnim Choudhury 1, Marilyn C Cornelis 3, Wanqing Liu 4 5 6
 
213.Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies
 

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1443-1450.e6. doi: 10.1016/j.cgh.2020.07.065.Epub 2020 Aug 5.

Nabihah Tayob 1, Douglas A Corley 2, Israel Christie 3, Lucy Almers 2, Ahmed K Rahal 4, Peter Richardson 3, Donna L White 3, Jessica Davila 3, Fasiha Kanwal 3, Hashem B El-Serag 5
 
214.External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population
 

Dig Dis Sci. 2021 Jul;66(7):2387-2393. doi: 10.1007/s10620-020-06501-1. Epub 2020 Aug 5.

Maya Balakrishnan 1, Aradhna Seth 2 3, Nahir Cortes-Santiago 4, Shilpa Jain 4, Gagan K Sood 5, Hashem B El-Serag 3, Aaron P Thrift 6 7
 
215.Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials
 

Diabetes Metab Res Rev. 2021 Sep;37(6):e3413. doi: 10.1002/dmrr.3413. Epub 2020 Oct 12.

Francisca Dos Santos Coelho 1 2, Marta Borges-Canha 1 2 3, Madalena von Hafe 1 2, João Sérgio Neves 1 2 3, Catarina Vale 1 2, Ana Rita Leite 1 2, Davide Carvalho 3 4, Adelino Leite-Moreira 1 2 5
 
216.Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study
 

Eur J Nutr. 2021 Jun;60(4):1769-1780. doi: 10.1007/s00394-020-02370-6. Epub 2020 Aug 28.

Cristina Galarregui 1, Irene Cantero 1, Bertha Araceli Marin-Alejandre 1, J Ignacio Monreal 2 3, Mariana Elorz 2 4, Alberto Benito-Boillos 2 4, José Ignacio Herrero 2 5 6, Víctor de la O 2 7, Miguel Ruiz-Canela 2 7 8, Helen Hermana M Hermsdorff 9, Josefina Bressan 9, Josep A Tur 8 10, J Alfredo Martínez 1 2 8, M Angeles Zulet # 11 12 13, Itziar Abete # 14 15 16
 
217.Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease
 

J Magn Reson Imaging. 2021 Jun;53(6):1623-1631. doi: 10.1002/jmri.27292.Epub 2020 Aug 21.

Jelte J Schaapman 1, Maarten E Tushuizen 2, Minneke J Coenraad 2, Hildo J Lamb 1
 
218.Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1258-1266.e1. doi: 10.1016/j.cgh.2020.08.012.Epub 2020 Aug 12.

Jun Wang 1, Anna H Wu 1, Frank Z Stanczyk 2, Jacqueline Porcel 3, Mazen Noureddin 4, Norah A Terrault 5, Lynne R Wilkens 6, Veronica Wendy Setiawan 7
 
219.Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018
 

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1499-1501.e2. doi: 10.1016/j.cgh.2020.08.017.Epub 2020 Aug 12.

Donghee Kim 1, George Cholankeril 2, Rohit Loomba 3, Aijaz Ahmed 2
 
220.Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD
 

Clin Gastroenterol Hepatol. 2021 Sep;19(9):1915-1924.e6. doi: 10.1016/j.cgh.2020.09.044.Epub 2020 Sep 30.

Tolga Gidener 1, Omar T Ahmed 1, Joseph J Larson 2, Kristin C Mara 2, Terry M Therneau 2, Sudhakar K Venkatesh 3, Richard L Ehman 3, Meng Yin 3, Alina M Allen 4
 
221.Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD
 

Dig Liver Dis. 2021 Sep;53(9):1154-1158. doi: 10.1016/j.dld.2020.09.021. Epub 2020 Oct 13.

Antonella Mosca 1, Annalisa Crudele 2, Antonella Smeriglio 3, Maria Rita Braghini 2, Nadia Panera 2, Donatella Comparcola 4, Arianna Alterio 4, Maria Rita Sartorelli 4, Giulia Tozzi 1, Massimiliano Raponi 5, Domenico Trombetta 3, Anna Alisi 6
 
222.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
 

Gut. 2021 Jul;70(7):1375-1382. doi: 10.1136/gutjnl-2020-322786. Epub 2020 Oct 9.

Tracey G Simon 1 2 3, Bjorn Roelstraete 4, Hamed Khalili 1 2 3, Hannes Hagström 5, Jonas F Ludvigsson 6 7 8 9 10
 
223.Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1267-1274.e1. doi: 10.1016/j.cgh.2020.09.045.Epub 2020 Oct 1.

Monika A Sarkar 1, Ayako Suzuki 2, Manal F Abdelmalek 2, Katherine P Yates 3, Laura A Wilson 3, Nathan M Bass 4, Ryan Gill 5, Marcelle Cedars 6, Norah Terrault 7, NASH Clinical Research Network
 
224.Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
 

Mol Metab. 2021 Aug;50:101122. doi: 10.1016/j.molmet.2020.101122.Epub 2020 Nov 19.

Kalliopi Pafili 1, Michael Roden 2
 
225.The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2199-2201. doi: 10.1016/j.cgh.2020.09.038.Epub 2020 Sep 30.

Hannah P Kim 1, Victor Navarro 2, Steven Zacks 3, Joseph Odin 4, David E Kleiner 5, Paul H Hayashi 6, Drug-Induced Liver Injury Network Investigators
 
226.Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19
 

Dig Dis Sci. 2021 Sep;66(9):3192-3198. doi: 10.1007/s10620-020-06618-3. Epub 2020 Sep 27.

Vincent L Chen 1, Fadi Hawa 2, Jeffrey A Berinstein 3, Chanakyaram A Reddy 3, Ihab Kassab 4, Kevin D Platt 3, Chia-Yang Hsu 3, Calen A Steiner 3, Jeremy Louissaint 3, Naresh T Gunaratnam 5, Pratima Sharma 3
 
227.ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis
 

Hepatology. 2021 Jun;73(6):2238-2250. doi: 10.1002/hep.31576. Epub 2021 Apr 19.

Luis Calzadilla-Bertot 1, Eduardo Vilar-Gomez 2 3, Vincent Wai-Sun Wong 4, Manuel Romero-Gomez 3, Rocio Aller-de la Fuente 5, Grace Lai-Hung Wong 4, Marlen Castellanos 6, Mohammed Eslam 7, Archita P Desai 2, Gary P Jeffrey 1 8, Jacob George 7, Naga Chalasani 2, Leon A Adams 1 8
 
228.Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard
 

Clin Infect Dis. 2021 Jun 15;72(12):2124-2131. doi: 10.1093/cid/ciaa429.

Veeral H Ajmera 1 2, Edward R Cachay 3, Christian B Ramers 4, Shirin Bassirian 1, Seema Singh 1, Richele Bettencourt 1, Lisa Richards 1, Gavin Hamilton 5, Michael Middleton 5, Katie Fowler 5, Claude Sirlin 5, Rohit Loomba 1 2 6
 
229.Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2202-2204. doi: 10.1016/j.cgh.2020.09.039.Epub 2020 Sep 30.

Samarth Patel 1, Mohammad Bilal Siddiqui 2, Jose Hernandez Roman 3, Emily Zhang 4, Emily Lee 4, Steve Shen 4, Masoud Faridnia 3, Robert J Mintini 5, Sherry Boyett 5, Michael O Idowu 6, Arun J Sanyal 1, Velimir A Luketic 1, Mohammad Shadab Siddiqui 1
 
230.Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1292-1293.e3. doi: 10.1016/j.cgh.2020.06.070.Epub 2020 Jul 3.

Vijay S Are 1, Raj Vuppalanchi 1, Eduardo Vilar-Gomez 1, Naga Chalasani 2
 
231.NAFLD and cardiovascular diseases: a clinical review
 

Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7.Epub 2020 Jul 21.

Philipp Kasper 1, Anna Martin 1, Sonja Lang 2, Fabian Kütting 1, Tobias Goeser 1, Münevver Demir 3, Hans-Michael Steffen 4 5
 
232.The relationship between excessive dietary fructose consumption and pediatric fatty liver disease
 

Pediatr Obes. 2021 Jun;16(6):e12759. doi: 10.1111/ijpo.12759. Epub 2020 Dec 11.

Johanna K DiStefano 1, Gabriel Q Shaibi 2
 
233.Liver disease in obesity and underweight: the two sides of the coin. A narrative review
 

Eat Weight Disord. 2021 Oct;26(7):2097-2107. doi: 10.1007/s40519-020-01060-w.Epub 2020 Nov 4.

Renata Risi 1, Dario Tuccinardi 2, Stefania Mariani 1, Carla Lubrano 1, Silvia Manfrini 3, Lorenzo Maria Donini 1, Mikiko Watanabe 1
 
234.Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease
 

Dig Dis Sci. 2021 Oct;66(10):3604-3611. doi: 10.1007/s10620-020-06673-w. Epub 2020 Oct 23.

Jonathan G Stine 1 2 3 4 5, Christopher Soriano 6, Ian Schreibman 7 8, Gloriany Rivas 7, Breianna Hummer 7, Esther Yoo 6, Kathryn Schmitz 9 10 11 12, Christopher Sciamanna 9 10 6
 
235.Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany
 

Dig Dis Sci. 2021 Sep;66(9):3179-3185. doi: 10.1007/s10620-020-06644-1. Epub 2020 Oct 10.

Christian Labenz 1 2 3, Karel Kostev 4, Leonard Kaps 1 3, Peter R Galle 1 2, Jörn M Schattenberg 5 6 7
 
236.Predicting Non-Alcoholic Fatty Liver Disease for Adults Using Practical Clinical Measures: Evidence from the Multi-ethnic Study of Atherosclerosis
 

J Gen Intern Med. 2021 Sep;36(9):2648-2655. doi: 10.1007/s11606-020-06426-5.Epub 2021 Jan 26.

Luis A Rodriguez 1, Stephen C Shiboski 2, Patrick T Bradshaw 3, Alicia Fernandez 4, David Herrington 5, Jingzhong Ding 6, Ryan D Bradley 7, Alka M Kanaya 2 4
 
237.Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection
 

Clin Infect Dis. 2021 Oct 5;73(7):e2184-e2193. doi: 10.1093/cid/ciaa1302.

James B Maurice 1 2, Robert Goldin 3, Andrew Hall 4, Jennifer C Price 5, Giada Sebastiani 6 7, Caryn G Morse 8, Laura Iogna Prat 2, Hugo Perazzo 9, Lucy Garvey 10, Patrick Ingiliz 11, Giovanni Guaraldi 12, Emmanouil Tsochatzis 2 13, Maud Lemoine 1
 
238.Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease
 

Clin Infect Dis. 2021 Aug 16;73(4):621-630.doi: 10.1093/cid/ciab019.

Takara L Stanley 1, Lindsay T Fourman 1, Lai Ping Wong 2, Ruslan Sadreyev 2, James M Billingsley 3, Meghan N Feldpausch 1, Isabel Zheng 1, Chelsea S Pan 1, Autumn Boutin 1, Hang Lee 4, Kathleen E Corey 5, Martin Torriani 6, David E Kleiner 7, Raymond T Chung 5, Colleen M Hadigan 8, Steven K Grinspoon 1
 
239.Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study
 

Obes Surg. 2021 Aug;31(8):3548-3556. doi: 10.1007/s11695-021-05402-0. Epub 2021 Apr 12.

Tatiana Codjia 1, Lionel Rebibo 2, Arnaud François 3, Carole Lagnel 4, Emmanuel Huet 5, Soumeya Bekri 4, François Pattou 6, Jean-Marc Régimbeau 2, Lilian Schwarz 5
 
240.Community screening identifies undiagnosed chronic liver disease in high-risk populations
 

Gastroenterol Hepatol. 2021 Aug;36(8):2255-2260. doi: 10.1111/jgh.15473. Epub 2021 Mar 17.

Salim Maher 1 2, Lisa Dowdell 1, Ling Zhang 1, Amany Zekry 1 2
 
241.Longitudinal associations of total and trunk fat in childhood and adolescence and risk of hepatic steatosis at 24 years
 

Pediatr Obes. 2021 Aug;16(8):e12773. doi: 10.1111/ijpo.12773. Epub 2021 Feb 8.

Catherine C Cohen 1, Ahlia Sekkarie 2, Janet Figueroa 1, Scott E Gillespie 1, Miriam B Vos 1 2 3, Jean A Welsh 1 2 3
 
242.Omega-3 Use for the Treatment of Hypertriglyceridemia, Low High-Density Lipoprotein Cholesterol Levels, and Nonalcoholic Fatty Liver Disease in Children with Obesity
 

Child Obes. 2021 Jul;17(5):357-364. doi: 10.1089/chi.2021.0047. Epub 2021 Apr 12.

Kristin M W Stackpole 1, Nicholas J Ollberding 2 3, Laurie A Smith 2, Paula Casson 4, Shelley Kirk 1 3, Robert Siegel 1 3
 
243.Unhealthy Eating, Psychopathology, and Nonalcoholic Fatty Liver Disease in Youth Presenting for Bariatric Surgery
 

J Pediatr Gastroenterol Nutr. 2021 Jul 27. doi: 10.1097/MPG.0000000000003253.Online ahead of print.

Sanita L Ley 1, Meg H Zeller, Jennifer Reiter-Purtill, David E Kleiner, John Dixon, Stavra Xanthakos, Teen View Study Group and in collaboration with the Teen-LABS Consortium
 
244.Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
 

BMJ Open Gastroenterol. 2021 Jul;8(1):e000678. doi: 10.1136/bmjgast-2021-000678.

Jadine Scragg 1 2, Kate Hallsworth 1 3, Guy Taylor 4, Sophie Cassidy 4, Laura Haigh 1 3, Marie Boyle 1 3, Quentin Anstee 1 3, Stuart McPherson 1 3, Leah Avery 5 6
 
245.The role of zinc in the prevention and treatment of nonalcoholic fatty liver disease
 

Metabol Open. 2021 Jun 29;11:100105. doi: 10.1016/j.metop.2021.100105. eCollection 2021 Sep.

Mary Barbara 1 2, Ayse L Mindikoglu 1 2
 
246.Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention
 

J Hepatol. 2021 Jul 30;S0168-8278(21)01954-1. doi: 10.1016/j.jhep.2021.07.025.Online ahead of print.

Naomi F Lange 1, Pompilia Radu 2, Jean-François Dufour 2
 
247.Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome
 

Diabetes Metab Syndr. 2021 Jul 28;15(5):102232.doi: 10.1016/j.dsx.2021.102232.Online ahead of print.

Stewart G Albert 1, Emily M Wood 2
 
248.Preparing for the NASH epidemic: A call to action
 

Obesity (Silver Spring). 2021 Sep;29(9):1401-1412. doi: 10.1002/oby.23250.Epub 2021 Aug 8.

Fasiha Kanwal 1, Jay H Shubrook 2, Zobair Younossi 3, Yamini Natarajan 4, Elisabetta Bugianesi 5, Mary E Rinella 6, Stephen A Harrison 7, Christos Mantzoros 8, Kim Pfotenhauer 9, Samuel Klein 10, Robert H Eckel 11, Davida Kruger 12, Hashem El-Serag 4, Kenneth Cusi 13
 
249.A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis
 

Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087. Online ahead of print.

Jaime Bosch 1 2, Chuhan Chung 3, Oscar M Carrasco-Zevallos 4, Stephen A Harrison 5, Manal F Abdelmalek 6, Mitchell L Shiffman 7, Don C Rockey 8, Zahil Shanis 4, Dinkar Juyal 4, Harsha Pokkalla 4, Quang Huy Le 4, Murray Resnick 4, Michael Montalto 4, Andrew H Beck 4, Ilan Wapinski 4, Ling Han 3, Catherine Jia